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The inactivation of tumor suppressor genes, which often results from 
epigenetic silencing associated with DNA hypermethylation, plays a pivotal 
role in the development of most forms of human cancer. Moreover, there are 
several reports demonstrating a strictly link between DNMT1 disregulation 
and oncogenensis. Nucleoside analogues effectively inhibit the activity of 
DNA methyltransferases, but their high cytotoxicity make the development of 
non-nucleoside inhibitors highly desirable. Procaine and procainamide exhibit 
a weak DNA demethylating activity and are “repositionable” as non-
nucleoside inhibitors. In this thesis, two series of Δ
2
-isoxazoline constrained 
analogues of procaine/procainamide are prepared and their inhibitory activity 
against DNMT1 is tested. Among them, 5b is far more potent in vitro (IC50 = 
150 μM) than other inhibitors and exhibits a dose-dependent antiproliferative 
effect against HCT116 human colon carcinoma cells. On the basis of 
competition assays, we assesse that 5b competes with the cofactor and propose 
it as a novel lead compound for the development of new, longer compounds, 
obtained by the combination of this SAM-competitive scaffold with 
“warheads” targeting the nucleotide binding site, as “bisubstrate” inhibitors of 
DNMT1.  
Moreover, starting from a virtual screening approach, the synthesis of the 
six top scoring compounds, obtained by the analysis of the NCI database, is 
reported. Among them, NSC140052 results the most powerful compound of 
this series, becoming the starting point for the synthesis of a small library of 
new compounds. 
Finally, a scalable two-step continuous flow synthesis of nabumetone and 
relate 4-aryl-2-butanones has been developed. As demonstrated for the 
synthesis of 4-(4-methoxyphenyl)-3-buten-2-one (52b), a throughput of 0.35 
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1.1. Epigenetics 
Chromatin structure defines the state in which genetic information in the 
form of DNA is organized within a cell, influencing the abilities of genes to be 
activated or silenced. Epigenetics, originally defined by C. H. Waddington
1
 as 
„the causal interactions between genes and their products, which bring the 
phenotype into being‟, involves understanding chromatin structure and its 
impact on gene function. Nevertheless, the definition of epigenetics has 
evolved over time as it is implicated in a wide variety of biological processes: 
the current definition is „the study of heritable changes in gene expression that 
occur independently of changes in the primary DNA sequence‟. Most of these 
changes are established during differentiation and are stably maintained 
through multiple cycles of cell division, enabling cells to have distinct 
identities while containing the same genetic information. This heritability of 
gene expression patterns is mediated by epigenetic modifications, which 
include methylation of cytosine bases in DNA or post-translational 
modifications of histone proteins. Failure of the proper maintenance of 
heritable epigenetic marks can result in inappropriate activation or inhibition 
of various signaling pathways and lead to disease states such as cancer.
2,3
 
These findings have led to a global initiative to understand the role of 
epigenetics in the initiation and propagation of this disease.
4
 The fact that 
epigenetic aberrations, unlike genetic mutations, are potentially reversible and 
can be restored to their normal state by epigenetic therapy makes such 




1.2. DNA methylation  
Epigenetic regulation can be separated into three inter-related layers: DNA 
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methylation is probably the most extensively studied epigenetic mark. It plays 
an important part in genomic imprinting, in DNA repair, in X-chromosome 
inactivation, and in the silencing of retrotransposons, repetitive elements and 
tissue-specific genes.  
DNA methylation in humans occurs almost exclusively in the context of 
CpG dinucleotides
7 , 8
 clustered in ~1 kb regions, termed CpG islands.
9
 In 
addition, it also occurs at regions of lower CpG density that lie in close 
proximity (~2 kb), termed “CpG island shores”.
10 , 11
Only < 80% of the 
methylatable CpG population, which represent over 50% of promoters, is 
methylated. Different CpG sites are methylated in different tissues, creating a 
pattern of methylation that is gene and tissue specific.
12
 This pattern creates a 
layer of information that confers upon a genome its specific cell type identity.  
Moreover, DNA methylation patterns in vertebrates are distinguished by 
their tight correlation with chromatin structure. Active regions of the 
chromatin, which enable gene expression, are associated with hypomethylated 
DNA, whereas hypermethylated DNA is packaged in inactive chromatin. 
Therefore, DNA methylation is a highly effective mechanism for silencing 
of gene expression in vertebrates and plants, either by interfering with the 
binding of transcription factors,
13,14
 or by attracting methylated DNA-binding 
proteins (MBDs), able to recruit other proteins and histone modifying 
enzymes, which leads to formation of a closed chromatin configuration and 
silencing of gene expression. Noteworthy, DNA methylation patterns are 
altered in the progression of cancer. Both the hypomethylation and 
hypermethylation of different regions of the genome play roles in contributing 
to tumorigenesis. During the development of tumors, a genome-wide 
demethylation occurs and this can promote genomic instability possibly by 
activating silenced retrotransposons.
15
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hypermethylation of CpG islands has been intensively studied in cancer. 
Nearly all types of cancers have transcriptional inactivation of tumor 
suppressor genes due to DNA hypermethylation.
6
 However, the exact 
mechanism responsible for the appearance of DNA methylation in a given 
promoter is not fully understood. 
The establishment and maintenance of DNA methylation patterns are 




1.2.1. Chemistry of DNA methylation  
 Methylation of DNA occurs immediately after replication by a transfer of a 
methyl moiety from the donor S-adenosyl-L-methionine (SAM, or AdoMet) in 
a reaction catalyzed by DNMT. In mammals, DNMTs preferentially methylate 
position 5 of a cytosine in a 5ꞌ-CpG-3ꞌ (CpG dinucleotide) context, although 
non- CpG methylation (CpA, CpT or CpC) has been described.
17
  
First, it has been shown that the targeted cytosine is flipped out of the DNA 
double helix into the catalytic site of the enzymes.
18
The thiolate of the 
catalytic cysteine in motif IV performs a nucleophilic attack on the 6-position 
of the cytosine, leading to the formation of the corresponding enamine (Figure 
1.1). The tripeptide in motif VI, containing a glutamine residue, allows the 
subsequent protonation in N3-position. A nucleophilic attack of the enamine 
on the SAM cofactor is followed by deprotonation of the C5 by a base 
(depending on the DNMT) in the active site, releasing a molecule of S-
Adenosyl-L-Homocysteine (SAH). The methyl group creates a steric clash 
that favors the -elimination, allowing the recycling of the enzyme and release 
of the methylated DNA substrate.
19
 The added methyl group now allows the 
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Figure 1.1. Mechanism of reaction catalyzed by cytosine C5 DNA methyltransferases. 
 
1.3. DNA Methyltransferases (DNMTs) 
In mammals, DNA nucleotide methyltransferases (DNMTs) include four 
members, in two families that are structurally and functionally distinct. The 
DNMT3 family establishes the initial CpG methylation pattern,
20
 whereas 
DNMT1 maintains this pattern during chromosome replication and repair.
21
 
The DNMT3 family includes two active methyltransferases, DNMT3A and 
DNMT3B, and one regulatory factor, DNMT3-Like protein (DNMT3L). 
DNMT1 shows preference for hemimethylated DNA in vitro, which is 
consistent with its role as a maintenance DNMT, whereas DNMT3A and 
DNMT3B methylate unmethylated and methylated DNA at an equal rate, 
which is consistent with a de novo DNMT role.
22
  
DNMT2 appears to provide an example of divergent evolution: it was 
named based on its high sequence and structural similarity to known DNA 
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The catalytically active DNMTs share common features, especially a 
regulating N-terminal domain and a catalytic C-terminal domain, particularly 
conserved among different species,
23,24
 including ten sequence motifs (I to X), 
which form the binding site for the cofactor S-Adenosyl-L-Methionine 
(SAM). Motif IV includes the proline-cysteine dipeptide bearing a catalytic 
thiolate group. Motif VI contains the glutamine residue allowing the 
protonation of the 3-position of the cytosine and motif IX maintains the 
recognition site of the targeted cytosine base (Figure 1.2).
25
  
Figure 1.2. Schematic representation of the human DNMT1, TRDMT1 and DNMT3s. 
 
On the other hand, the N-terminal part of DNMTs binds to DNA and has 
several protein recognition domains, guiding the DNMTs to the nucleus, to 
chromatin and to numerous proteins, hence tightly linking chromatin 
modulation and DNA methylation. 
 
1.3.1. Mammalian DNMTs: characterization and biological role 
1.3.1.1. DNMT1 
The DNMT1 (Figure 1.3) was the first DNMT to be purified and 
characterized.
26 , 27
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 has 1616 amino acids and can be found as three isoforms in 
almost every eukaryotes: DNMT1s (somatic cells), DNMT1o (oocyte) and 
DNMT1p (pachytene).
29
 As it has a greater affinity for hemimethylated DNA 
than unmethylated, it intervenes mainly after DNA replication to methylate the 
newly synthesized strand.
30,31





Figure 1.3. The crystal structure of the mDNMT1(650–1602)–DNA 19-nucleotide oligomer 
complex. The CXXC, BAH1, and BAH2 domains and CXXC-BAH1 linker of mDNMT1 
have been removed for clarity. The bound DNA is in light brown, with the TRD and catalytic 
core in light and dark blue, respectively.  
 
Disruption of the Dnmt1 gene in mice can lead to significant demethylation of 
the genome and strong embryonic lethality. In non-tumoral cells, conditional 
or total knockout of DNMT1 leads to apoptosis,
33
 severe mitotic defects
34
 and 
tumorigenesis through chromosomal instability.
35,36
 These results indicate that 
DNMT1 is essential, both during developmental stages and in somatic cells, to 
ensure cell proliferation and survival. In cancer cells, disruption of DNMT1 





                                                                                         Chapter 1:Introduction 
- 9 - 
 




DNMT1 is responsible for the maintenance DNA methylation via two 
different mechanisms: (i) through its direct interaction with the replication 
fork and (ii) as an interacting partner of UHRF1 (ubiquitin-like, containing 
PHD and RING finger domains 1).
38
 Indeed, at the beginning of the S phase in 
somatic cells, DNMT1 is transported to the nucleus, thanks to a nuclear 
location signal (NLS), and more precisely to the replication foci through a 
specific sequence located within its N-terminal domain (Targeting Replication 
Foci: TRF) and its PCNA (Proliferating Cell Nuclear Antigen) binding domain 
(PBD). It then binds to hemimethylated DNA.
39 , 40
 The cytosine to be 
methylated is flipped out into the catalytic pocket and the methyl group of the 
SAM cofactor is transferred to position 5. Once the first CpG has been entirely 
methylated, DNMT1 moves along the newly synthesized DNA strand to 
further methylate.  
The second mechanism implies UHRF1, a protein that has a specific 
affinity for hemimethylated CpG sites and recruits DNMT1 at these sites. 
Overall, the maintenance of DNA methylation patterns possesses a gross error 
frequency of circa 5% per CpG site and per cellular division. This leaves to 
cells some flexibility for subtle but probable important changes in their 
methylation pattern. This is balanced by DNMT3A and 3B that help DNMT1 
in the maintenance of the methylation profile during replication.
41
  
DNMT1 has a number of sequence motifs shared with other proteins but of 
unknown or unconfirmed function. DNMT1 contains two bromo-adjacent 
homology (BAH) domains, which are also found in origin recognition 
complex proteins and other proteins involved in chromatin regulation. The 
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Near the center of the N-terminal domain is a cysteine-rich region that binds 
zinc ions, present in all confirmed mammalian cytosine methyltransferases, 
known mammalian proteins affecting cytosine methylation, as well as the 






Figure 1.4. Structure of human DNMT2. 
 
The DNMT2 enzyme (Figure 1.4) was originally assigned as a member of 
the DNA methyltransferase family on the basis of its very high degree of 
similarity in sequence and structure to eukaryotic and prokaryotic DNA-
(cytosine C5)-methyltransferases. DNMT2 is strongly conserved and can be 
found in species ranging from Schizosaccharomyces pombe to humans, 
suggesting a very important role in cellular homeostasis.  
The former DNMT2 has been recently renamed as TRDMT1 since it does 
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It has only a very small DNA methyltransferase activity in vitro 
and in vivo, suggesting that the N-terminal domain is not absolutely required 
for this activity, but more for its regulation.
45
  
Whereas depletion of DNMT1, DNMT3A, DNMT3B and even DNMT3L 
genes lead to abnormal phenotypes (male sterility, developmental problems) 
or even to embryonic death,
46
 the depletion of the TRDMT1 gene does not 
lead to any phenotypic modification. It is, thereby, hypothesized that this 
enzyme might be particularly useful not during the embryonic development, 
but rather during species evolution. 
 
1.3.1.3. DNMT3 family 
The mammalian genome encodes two functional cytosine 
methyltransferases of the DNMT3 family, DNMT3A and DNMT3B, which 
primarily methylate CpG dinucleotides, and a third homologue, DNMT3L, 
which lacks cytosine methyltransferase activity and functions as a regulatory 
factor in germ cells.  
DNMT3A has been identified as responsible for the imprinting of genes 
and methylates mainly pericentromeric regions of the DNA, while DNMT3B 
seems to methylate centromeric regions.
47
 Furthermore, mutations on this 
latter lead, among other defects, to immunodeficiency syndromes and 
centromeric instabilities.  
DNMT3L lacks the catalytic motif and thus shows no methylation activity 
by itself (Figure 1.2).
48,49
 Actually, it is a cofactor of DNMT3A and interacts 
with histone modifying proteins thus keeping DNA methylation connected to 
histone modifications. The X-ray crystal structure of the mouse catalytic 
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3L, suggesting the simultaneous methylation of two CpG sites at one helix 
turn away from one another (circa 10 bp).
50
 In addition, it was shown that the 
complex oligomerizes on the DNA
51
 and that DNMT3A/3B are the only 
DNMTs to possess the proline-tryptophane-tryptophane-proline (PWWP) 
sequence, which allows them to directly bind DNA.
52
 
Finally, DNMTs can interact with one another. For example, the N-terminal 
part of DNMT1 can bind to DNMT3A/3B N-terminal part, conferring to 
DNMT1 a de novo methylation activity.
53,54
 Similarly, DNMT3 enzymes can 
act as maintenance methyltransferases, in a DNMT1 deficient background.
55
 
Therefore the strict separation of maintenance and de novo activity between 




1.4. DNA methylation and pathologies 
Considering their role in the regulation of gene transcription, DNA 
methylation (as the other epigenetic marks) is essential for crucial processes 
such as embryonic development or differentiation and is involved in various 





With the increasing accessibility to genome-wide techniques to study DNA 
methylation, numerous pathologies have been linked to epigenetic disruptions, 
particularly diseases that are influenced by the environment. Indeed, since 
DNA methylation is required in the memory process, it has recently been 
proved to have an important role, not only in Alzheimer‟s disease,
59
 but also in 
psychiatric diseases (depression, bipolar disorder, schizophrenia).
60
  
DNA methylation is clearly involved in auto-immune diseases
61
 and even 
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disease, atherosclerosis.).
62 , 63  
Besides, aberrant DNA methylation patterns 
have been extensively described in numerous cancers.  
It has been shown that cancer cells display a global hypomethylation
64
 and 
at the same time a hypermethylation of certain gene promoters.
65
 On the one 
hand, hypomethylation leads to chromosomal instability, since repeated 
sequences are no longer methylated. On the other hand, hypermethylation 
leads to silencing of Tumor Suppressor Genes (TSG).  
As mentioned above, the reversibility of DNA methylation represents an 
interesting strategy in oncology. Hence, the use of specific inhibitors of 
DNMT (DNMTi) might reactivate TSG and induce the reprogramming of 




                          
Figure 1.5. Stability and reversibility of epigenetic mutations. 
 
Nevertheless, depleting either one DNMT is sufficient to suppress in vitro 
cell growth. In addition, several studies clearly demonstrated that DNMT1 
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growth arrest in various in vitro cancer cells such as lung, esophagus, stomach, 
breast, cervix, brain, head and neck.
67,68
  
Overall, these data strongly argue in favor of a selective inhibition of 
DNMT, and in particular of DNMT1, to achieve an antitumor effect.  
 
1.5. DNMT inhibitors (DNMTi) 
As discussed above, tumor suppressor genes hypermethylation is often 
involved in cancers and, because of its reversibility, their demethylation 
constitutes an interesting therapeutic strategy. Many DNMT inhibitors have 
been described and are divided into two families: the nucleoside analogues, 
that have been known and studied for many years, and the non-nucleoside 
inhibitors, which structure varies according to their inhibitory mechanism. 
 
1.5.1. Nucleoside analogues 
1.5.1.1. First generation molecules: azacitidine, decitabine and zebularine 
Until now, several DNMT1 inhibitors have been identified. They can be 
divided into different groups. The first one includes cytidine analogs like 5-
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The nucleoside analogues 5-azacytidine (5-Aza-CR) and 5- aza-2ꞌ-





), respectively, are the two most potent DNMTi. In this 
molecules, the carbon atom in position 5 is replaced by a nitrogen atom and 
linked to a ribose or a deoxyribose, respectively (Figure 1.6).  
To be active, these compounds need to be integrated into the genome 
during the S phase (replication) of the cell cycle, allowing a certain specificity 
towards rapid proliferating cancer cells (Figure 1.7).  
 
             
Figure 1.7. Mechanism of action of nucleoside analogue inhibitors. Deoxynucleoside 
analogues are depicted by Z. Pink circles, methylated CpG; cream circles, unmethylated CpG. 
 
Once into the DNA, the cytosine analogues are recognized by the DNMTs 
and undergo the same reaction as normal cytosines, with the formation of the 
covalent intermediate between the catalytic cysteine of the enzyme and 6-
position of cytosine analogues. However, unlike with cytosine, the -
elimination reaction can no longer occur because of the presence of the 
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enzyme is thereby trapped by the suicide inhibitor, triggering its proteasomal 
degradation. 
At higher doses, these compounds are cytotoxic, therefore they are used at 
low doses in order to achieve only the demethylation effect with little 
cytotoxicity. Besides the DNMT inhibition, the ribose analogues are also 
incorporated into RNA, decreasing the incorporation into DNA and disrupting 
protein synthesis. This might explain why decitabine is more active than 
azacitidine, but also why it has also less significant secondary effects, given 
that the latter can be incorporated not only in dividing cells, but also in 
quiescent cells. 
Together with the HDACi (Histone deacetylase inhibitors), these two 
compounds are the only “epidrugs” that have been approved, so far, against 
Myeloid Dysplasic Syndrome (MDS), Acute Myeloid Leukemia (AML) and 
Chronic Myelomonocytic Leukemia (CMML) for Vidaza
®
 by FDA in 2004 
and the European Medicines Agency (EMA), and against MDS and AML for 
Dacogen
®
 by FDA in 2006. However, these two DNMT inhibitors are not 
selective towards the different DNMTs and have strong secondary effects, e.g. 
renal toxicity and myelotoxicity.
70
  
Moreover, 5-Aza-CR and 5-Aza-CdR are readily hydrolyzed in aqueous 
solution and subject to deamination by cytidine deaminase. The instabilities of 
these compounds inevitably present a challenge to their clinical applications. 
To improve the stability and efficacy of 5-Azanucleosides, several other 
cytidine analogues have been developed. For example, zebularine (a cytidine 
analogue that lacks an amino group in the 4 position of the pyrimidine ring) 
can inhibit DNMTs and cytidine deaminase after oral administration.
71
 The 
inefficient metabolic activation of this compound has, however, delayed its 
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Compared to the suicide analogues, zebularine is used at higher 
concentrations to obtain the same demethylation levels in cells but is 
associated with lower cytotoxicity. Nevertheless, no new information related 
to a possible clinical development of zebularine has been published recently. 
Moreover, recent studies have shown that, depending on the used nucleoside 
analogue (azacitidine, decitabine or zebularine), demethylation patterns of 
tumor suppressor genes promoters are different, reflecting complex and 
partially overlapping mechanisms of action. 
The use of these drugs raises questions regarding their potential to affect 
non-cancerous cells epigenetically. However, normal cells divide at a slower 
rate than malignant cells and incorporate less of these drugs into their DNA 
resulting in less of an effect on DNA methylation. Also, long-term negative 





1.5.1.2. Second generation molecules: pro-drugs 
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The success of azacitidine and decitabine as DNMTs inhibitors in human 
chemotherapy prompted researchers to identify new compounds with a better 
pharmacokinetic profile. An elaidic acid ester of azacitidine, CP-4200 (Figure 
1.8), has been synthesized with the aim of improving the drug cellular uptake. 
Several cellular assays highlighting the positive effect of CP-4200 on DNA 
demethylation as well as the dependency on nucleoside transporters have been 
conducted in comparison with azacitidine. It was demonstrated that CP-4200 
acts as a pro-drug of azacitidine, presenting the advantage of a delayed 
delivery of the chemically instable azacitidine.
73
 
SGI-110 (formerly S-110, Figure 1.8) is a second generation DNMT 
inhibitor that acts as a decitabine pro-drug. SGI-110 is a dinucleotide 
decitabine-p-deoxyguanosine as stable as decitabine in aqueous solution but 
more resistant to cytidine deaminase. In vivo, this enzyme is responsible for 
the deamination reaction of decitabine into the inactive 5-azadeoxyuridine.
74
 
SGI-110 is currently in Phase II clinical trials for the treatment of MDS and 
AML.  
These nucleoside-like inhibitors have proved their efficiency in various 
clinical trials, but their lack of specificity and their strong secondary effects 
lead to an urgent need for novel more selective DNMT inhibitors. 
 
1.5.2. Non-nucleoside analogues 
A particular interest has recently emerged from non-nucleoside molecules, 
whose mechanism does not rely on DNA incorporation. Thus, some DNMT 
inhibitors of various origins and structures have been described during the last 
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these molecules are compounds that have already demonstrated a biological 
action against other targets than DNMTs.  
Differently from nucleoside analogues, non-nucleoside inhibitors exhibit a 
wide structural diversity, and can be divided in the following groups. 
 
1.5.2.1. Natural compounds: flavonoids, psammaplin A and curcumin 
              
Figure 1.9. Flavonoids as DNMT inhibitors. 
 
Flavonoids (or bioflavonoids) are organic compounds mainly extracted 
from plants, where they fulfill numerous functions, for example plant 
pigments or antifungal activity. One of the most studied flavonoid is (-)- 
epigallocatechin-3-O-gallate (EGCG, Figure 1.9). It is the main polyphenol of 
the green tea and its preventive anti-cancerous properties have been regularly 
reported in the literature for many years,
75
 along with its numerous targets 
(protein kinases, highly reactive hydrogen peroxides).  
Another well-known molecule of this wide family is genistein (Figure 1.9). 
It was first extracted from Genista tinctoria (Dyer‟s Broom) in 1889 by Perkin 
and Newbury, then characterized in 1926 and first synthesized in 1928 by 
Baker and Robinson.
76
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soybean and has been initially considered a phytoestrogenic molecule, then a 
potential anticancer agent because of its in vitro activity again diverse 
enzymes such as tyrosine kinases, protooncogene HER-2, topoisomerase I or 
II, protein histidine kinase as well as G2/M block of cell cycle inducer. 
Recently, both EGCG and genistein have been characterized as enzymatic 
and cellular DNMT inhibitors, being able to demethylate RAR, p16
INK4a
 and 
MGMT promoter leading to the re-expression of these tumor suppressor 
genes.
77
 The supposed mechanism of action of flavonoids relies on an indirect 
inhibition of DNMTs: more precisely, they are substrate of the Catechin-O-
Methyltransferase (COMT), a SAM-dependent enzyme, and, as flavonoids 
became methylated, the SAH concentration increases. Since the intracellular 
SAM/SAH equilibrium is displaced and considering that SAH is a potent 
DNMT inhibitor, the DNMTs are no longer able to methylate.  
These two flavonoids are now regarded more as chemopreventive drugs 
than actual treatment drugs, even though their metabolisms drastically 
decrease their biodisponibility, hence lowering their potential activity. 
 
 
Figure 1.10. Structure of Psammaplin A. 
 
Psammaplin A (Figure 1.10) is a natural compound extracted for the first 
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derivatives of 3-bromotyrosine. It possesses both antibacterial and antitumor 
properties, and was synthesized by Hoshino et al. in 1992.
78
  
Psammaplin A was described as inhibitor of about ten different enzymes, 




In a systematic study of several natural derivatives of psammaplin A, it has 
been shown an activity against DNMT1 and HDACs. Antiproliferative 
properties of psammaplin A have also been explored on MDA-MB- 435 and 
A549 cell lines (breast and lung cancer, respectively) with promising results, 
since it inhibits cell growth at low doses (IC50 = 2 mM). Nevertheless, no 
DNA demethylation has been highlighted in HCT116 cells,
80
 and, in a recent 





Figure 1.11. Structure of curcumin. 
 
Curcumin (Figure 1.11) and derivatives were selected on the bases of the 
chemical reactivity of their α,-unsaturated carbonyl motif towards cysteine 
thiol functions. Experimental inhibition of the bacterial C5-DNA 
methyltransferase M. SssI was confirmed for curcumin and derivatives with 
IC50 around 30 nM.
82
 Finally, curcumin at doses higher than 3 mM induced a 
decrease of global DNA demethylation of leukemia MV4-11 cells.  
Despite these results, this molecule and various analogues are known to 





Chapter 1:Introduction                                                                                                  a 
- 22 - 
 
pharmacological activities have been demonstrated in in vivo models neither in 
human therapy although the large number of clinical trials.  
 
1.5.2.2. Inhibitors identified by virtual screening: nanaomycin A and RG108 
 
 
Figure 1.12. Structure of nanaomycin A. 
 
Nanaomycin A (Figure 1.12) is a quinone antibiotic isolated in 1975 from a 
Streptomyces strain. Its DNMT1 potential inhibitory properties have been 
deduced after a virtual in silico screening,
83
 but exhibited no activity when 
evaluated on DNMT1 biochemical assay. During further investigations, quite 
surprisingly, nanaomycin A demonstrated a selective inhibition of DNMT3B. 
Subsequent cellular characterization was undertaken, namely cytotoxicity 
evaluations and DNA methylation level examination on three cancer cell lines 
(A549, HCT116 and HL60, lung, colon and leukemia cell lines, respectively). 
Molecular docking calculation using a homology model of DNMT3B resulted 
in a possible model of nanaomycin A into the catalytic domain. However, 
despite the effects observed on the enzyme and a weak but significant 
demethylation of the RASSF1A promoter region, the authors concluded that 
DNMT3B inhibition is not the only mechanism of action of nanaomycin A 
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Figure 1.13. Structure of the phtalimido-L-tryptophan RG108. 
 
Like nanaomycin A, RG108 (Figure 1.13) is a DNMT inhibitor found by 
virtual screening on DNMT1.
85
 Siedlecki et al.
86
 previously established a 3D 
model of the catalytic domain of DNMT1 by homology with the crystalline 
structures of bacterial methyltransferases M. HhaI, M. HaeIII and human 
methyltransferase TRDMT1. They carried out a virtual screening of a small 
molecules database (NCI database) revealing a simple phthalimido-L-
tryptophan skeleton, named RG108, as hit. RG108 inhibits in vitro M. SssI 
and human DNA methylation in HCT116 and NALM6 (leukemia) cells at 100 
mM. Moreover, it has been proved that it can reactivate tumor suppressor 
genes such as P16
INK4a
 and TIMP3, which are repressed by promoters 
methylation in the cancer cell line HCT116.  
Different studies also demonstrated that, at the contrary to other DNMTs 
inhibitors, RG108 is neither genotoxic, nor cytotoxic, and that it prevents the 
substrate to enter the catalytic pocket: a carbonyl group of RG108 is 
positioned at the level of the 6-position of the cytosine, which can prevent the 
formation of a covalent bond between the cytosine and the thiolate of the 
catalytic cysteine.  
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1.5.2.3. Drugs used for other indications: SGI-1027, hydralazine, procaine 
and procainamide  
 
Figure 1.14. Structure of SGI-1027. 
 
SGI-1027 (Figure 1.14) is a lipophilic quinoline inhibiting DNMT1, 3A and 
3B that was initially synthesized for its antitumor activities. Indeed, 
quinolinium salts are known to be reversible but also strong ligands of the 
DNA minor groove, causing cell death by a still unknown mechanism.
88
  
On the contrary, SGI-1027 is a weak base that binds only weakly to AT-
rich DNA (IC50 = 0.51 mM for the binding to poly(dA-dT)), but has a 
relatively good stability in physiological media. Its activity was tested in vitro 
on bacterial M. SssI and on mammalian DNMTs.
89
  
SGI-1027 is not a competitive inhibitor of DNA but of the cofactor SAM. 
Besides, it has been observed a rapid proteasomal degradation of DNMT1 
after treatment of HCT116 and RKO (colon cancer) by SGI-1027. Even if the 
degradation seems specific to DNMT1 and suggests a different and not yet 
known mechanism (sharing the same signal pathway as the nucleoside 
analogues), all DNMTs are inhibited by SGI-1027 because of the very 
conserved motifs I and X (involved in the recognition of the SAM cofactor). 
Finally it demethylates and re-expresses TIMP3 and P16
INK4a
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Figure 1.15.Structure of the antihypertensive hydralazine. 
 
Hydralazine (Figure 1.15) is used in the treatment of hypertension and its 
secondary effects have allowed to discovery its DNMT inhibitory action. 
Despite its frequent use for numerous years, its mechanism remains unknown. 
Indeed, hydralazine induces the erythematosus lupus in treated patients and 
this autoimmune disease is associated with a hypomethylation of T cells, 
confirmed on T cells in culture.
90
  
Hydralazine has been tested in phase I on patients who have developed 
ovary tumors, resulting in demethylation-induced reactivation of tumor 
suppressor genes in few cases and a mild overall tolerance by patients. 
Moreover, hydralazine is currently tested in phase III on patients that have 
developed brain or ovary tumors and also in phase II against chemo-resistant 
tumors. It is currently in phase II in combination with magnesium valproate, 
an HDAC inhibitor, and registered in Mexico in the treatment of MDS. 
Hydralazine is therefore, a promising molecule in anti-cancer treatments, even 
if its therapeutic scope is restricted to very few cancers. Indeed, its efficiency 
being limited to a narrow range of cells might turn into an advantage. A 
specific targeting would circumscribe secondary effects and decrease the risk 
to induce a global demethylation of the entire DNA, which could lead to a 
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Figure 1.16. Structures of procaine and procainamide. 
 
Procainamide and its ester analogue, procaine (Figure 1.16), have been used 
for the last 30 years as antiarhythmic and anesthetic agents, respectively. As 
for hydralazine, its DNMT inhibitory effects were discovered through their 
secondary effects. In the presence of procainamide, the rate of 5-
methylcytosine in Jurkat cells decreased, allowing the re-expression of some 
genes. The link between procainamide and DNA methylation was first 
established by demonstrating that procainamide and procaine have an affinity 
for the CpG-rich regions of DNA, and that are able to suppress growth in these 
breast cancer cells simultaneously with the occurrence of demethylating events 
(Figure 1.17).
91
      
 
Figure 1.17. (A) Measurement of 5-dmC content in MCF-7 cell lines treated with increasing 
concentrations of procaine (PCA) and decitabine (DAC) as a percentage of the total cytosine 
pool; (B) Mitotic index, the number of cells in metaphase, anaphase, or telophase  with respect 
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Two molecular modeling studies suggested that procainamide binds also to 
DNMT.
92,93
 A systematic in vitro and cellular study was carried out on human 
DNMTs, showing that procainamide inhibits preferentially DNMT1 in the 
presence of a hemimethylated substrate (KI = 7.2 ± 0.6 mM) than 
DNMT3A/3B in the presence of an unmethylated substrate (KI > 1000 mM).
94
 
This inhibition is competitive compared with the two substrates, SAM and 
hemimethylated CpG, which implies a decrease of the enzyme affinity for 
these two factors. The study also highlighted that the inhibition difference 
between hemimethylated and unmethylated DNA is not due to a difference in 
affinity of the enzyme for its various substrates. Finally, this studies showed 
that this inhibition is likely connected to a loss of DNMT1 processivity: by 
decreasing the affinity of DNMT1 for hemimethylated-DNA, procainamide 
facilitates the dissociation of the enzyme from the DNA.  
So why design new DNMTi? Importantly, DNMTi can be used to address 
two main issues: 1) the better understanding of DNA methylation in normal 
and cancer cells, and 2) the specific and efficient targeting of DNA 
methylation for therapy. In fact, while DNMTs are well-characterized 
enzymatically, their mechanism of action and their regulation in cells are still 
not completely elucidated and even less in cancer cells in which aberrant DNA 
methylation is observed. Small chemicals inhibiting DNA methylation can be 
useful tools to probe the methylation mechanism both at the enzymatic level 
and in cells. In parallel, it is also now well established that DNA methylation 
constitutes a promising therapeutical target in cancer, in particular, but also in 
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2.1. Aim of the work 
As known, the nucleoside-like inhibitors have proved their efficiency in 
various clinical trials, but their lack of specificity and their strong secondary 
effects lead to an urgent need for novel non-nucleoside DNMT inhibitors. 
Being interested in the development of small-molecule modulators of 
epigenetic targets, we decided to apply two different medicinal chemistry 
approaches: 
 1) we prepared a new series of 
2
-isoxazoline derivatives, following on our 
previous studies that led to the identification of a constrained analogue (3b) of 
procaine as a lead compound for the discovery of  new DNMT1 inhibitors; 
2) at the same time, we designed and synthesized a small collection of 
compounds taking advantage of a virtual screening approach. 
 
2.1.1. Frozen analogue approach: procaine/procainamide analogues 
With respect to the first approach used, we focused our attention on 
procaine/procainamide as a lead structure for further modification. Originally 
approved by the FDA as local anesthetic and antiarhythmic drug, respectively, 




It has been reported that procainamide specifically inhibits DNMT1 by 
reducing the affinity with hemimethylated DNA (substrate) and S-
adenosylmethionine (cofactor),
96
 thus causing growth arrest
94
 and reactivation 
of tumor suppressor genes in cancer cells.
97
 With the aim to increase potency, 
according to the frozen analogue approach, we decided to limit the very high 
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moiety into a 4-substituted- or 5-substituted-oxazoline ring (derivatives 1,2 
and 3,4, Figure 2.1). 
 
Figure 2.1. Frozen analogue approach of procaine/procainamide. 
 
Among the synthesized compounds, unexpectedly, the nitro derivative 3b 
exhibited the highest inhibitory potency against DNMT1 and, when tested for 
its effects on the genome methylation levels in HL60 human myeloid leukemia 





Figure 2.2. Cellular methylation assays. Human myeloid leukemia (HL60) cells were incubated for 72 h 
with DMSO (1%), procaine (0.5 mM), decitabine (0.5 μM), and test compound 3b (0.5 mM). COBRA assay of 
chromosomal satellite repeats (C1S2). DMSO treated cells revealed methylated satellites, but procaine as well 
as 3b induced minor demethylation of the repetitive elements. Decitabine treatment was included as positive 
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To extend structure-activity relationships for this new class of inhibitors, 
we needed a scaffold more stable and versatile than the oxazoline ring. 
Therefore, we decided to explore the possibility of replacing it with the Δ
2
-
isoxazoline (C, Figure 2.3) and to introduce a new conformational restriction 
(D, Figure 2.3). 
Once that the biological as well as binding mode investigations of the first 
two series of compound were completed (Chapter 4 and 5), we realized that 
they were able to occupy only a portion of the binding site of the enzyme. 
Therefore, being interested in the development of analogues endowed with 
improved enzyme binding properties and higher inhibitory potency, we 
decided to synthesize new, longer compounds, obtained by the combination of 
the SAM-competitive isoxazoline scaffold with “warheads” targeting the 
nucleotide binding site, as “bisubstrate” inhibitors of DNMT1. In particular, 
we designed a small collection of molecules bearing the pyrimidine scaffold, 
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2.1.2.  From virtual screening to new DNMT1 inhibitors 
At the same time, we paid attention to molecular modeling and virtual 
screening of compound databases, powerful computational techniques that are 
increasingly being used in drug discovery projects. These techniques are now 
commonly applied to understand the binding mode of active compounds and 
identify new hits.
83, 99
 In 2011, 260,000 compounds in the Diversity Set 
available from the National Cancer Institute (NCI) were the starting point to 
identify additional DNMT1 inhibitors. Six of the top scoring compounds were 
synthesized by us (Figure 2.4) in order to obtain their DNMT1 inhibitory 
activity in a biochemical assay.  
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Among them, NSC140052 showed a good and selective inhibitory activity 
against DNMT1 (IC50 = 220 µM), so we decided to realize a small library of 
compounds replacing both the -Cl group on the aromatic ring and the length of 
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3.1. 1,3-dipolar cycloaddition: an efficient strategy to 
2
-isoxazolines 
The 1,3-dipolar cycloaddition offers a convenient one-step route for the 
construction of a variety of complex five-membered heterocycles. 1,3-dipolar 
cycloadditions of in situ generated nitrile oxides with alkenes are well-





Aldoximes are established precursors of nitrile oxides, and different classes of 




The outcome of the reaction is strongly dependent on the nature of the 
dipolarophile. In fact, with reactive alkenes, it is possible to use a rapid and 
efficient method, characterized by the in situ formation of the nitrile oxide by 
the corresponding aldoximes after oxidative chlorination, followed by base-
induced dehydrochlorination of the intermediate hydroxymoyl chlorides. The 
so formed nitrile oxide reacts rapidly with the dipolarophile, and the reaction 
is complete within 15 minutes. 
Instead, with sluggish dipolarophiles, the 1,3-dipole must be generated 
slowly so as to disfavor dimerization of the nitrile oxide to give furoxan 
(1,2,5-oxadiazol-2-oxide) as an unwanted side product (Figure 3.1).  
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Slow generation of the nitrile oxide can be achieved by addition of an 
organic base by means of a syringe pump to a solution of the stable precursor 
hydroximoyl halide and the dipolarophile. Alternatively, an efficient strategy 
involves the use of a heterogeneous mixture of an organic solvent, e.g., ethyl 
acetate, and an inorganic base, e.g., NaHCO3 or KHCO3.
102
  
Both methods allow the maintenance of a low concentration of the dipole, 
thus preventing dimerization and promoting its reaction with the dipolarophile. 
The drawback of the above-described strategy is the slowness of the reaction, 
which can take up to several days or weeks. 
 
3.2. Synthesis of 
2
-isoxazolines (5a-l) 
The key step for the synthesis of Δ
2
-isoxazolines 5a-l was the 1,3-dipolar 
cycloaddition of nitrile oxides to allylic alcohol. Nitrile oxides were formed in 
situ by the corresponding aldoximes 7 after oxidative chlorination with 
aqueous NaOCl solution (common bleach), followed by base-induced 
dehydrochlorination of the intermediate hydroxymoyl chlorides (chloroximes). 
The cycloaddition reaction afforded alcohols 8 in good isolated yields (68-
93%) (Scheme 3.1). 
The nucleophilic displacement of the corresponding mesylates 9 with 
dimethylamine furnished derivatives 5a-d, 5h-j, and 5l. The carboxylic acid 
derivative 5e was obtained by deprotecting the t-butyl ester 5l with 
trifluoracetic acid at room temperature. The phenol derivative 5g was obtained 
from the corresponding tosylate 5d after hydrolysis with NaOH. Finally, 
reduction with zinc powder in acetic acid converted nitro derivatives 5b and 5i 





                                                                                          Chapter 3: Chemistry 
 - 41 -    
    
 
Scheme 3.1. Reagents and conditions: (a) 3% NaOCl, CH2Cl2, 0 °C to room temperature, 15 
min (68-93%); (b) MsCl, TEA, CH2Cl2, 0 °C to room temperature, 45 min (99%); (c) 
dimethylamine, THF, 100 °C, sealed tube, 12 h (75-81%); (d) TFA/CH2Cl2 1:3, room 
temperature, overnight (99%); (e) 1N NaOH, EtOH, reflux, 1 h (96%); (f) zinc powder, acetic 
acid, room temperature,1 h (63-75%) 
 




derivatives 12 were obtained exploiting the reactivity of different chloroximes 




 (Scheme 3.2) 
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3.3.1. Synthesis of the dipoles: the chloroximes  
The substituted chloroximes 10 were prepared employing a straightforward 
two-step strategy: the proper aldehydes were first converted in the 
corresponding oximes under standard conditions, then derivatives 7 were 
reacted with NCS in the presence of pyridine to give the corresponding 10a-d, 
10h-j, and 10l (Scheme 3.3). 
 
Scheme 3.3. Reagents and conditions: (a) NH2OH•HCl, Na2CO3, H2O/methanol 1:1, room 
temperature, 3 h (89-96%); (b) NCS, pyridine, CHCl3, 40 °C, 0.5–3h (99%). 
 
3.3.2. Optimizing the 1,3-dipolar cycloaddition 
As previously reported with other types of hydroxamoyl halides, N-Boc-
protected pyrroline 11 has a poor reactivity, and unless the generated dipole is 
highly reactive (e.g., bromonitrileoxide), the cycloaddition reaction gives low 
yields.
104
 Thus, a slow generation of the dipole is required.  
 
3.3.2.1. Conventional conditions 
We initially carried out the reaction under conventional reaction conditions: 
the nitrile oxide was generated in situ by treating chloroximes 10 with excess 
solid NaHCO3 in EtOAc, in the presence of alkene 11, and the reaction was 
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dipole, the addition of further aliquots of chloroxime over time was necessary. 
The cycloaddition reaction proceeded slowly, yielding less than 50% of the 
desired product after 7 days (Table 1.1). The yield was strongly dependent on 
the nature of the chloroxime, ranging from 45% (entry c, R=p-CH3O-Ph) to as 
low as < 2%(entry e, R=p-NO2-Bn).  
 
TABLE 1.1. Reaction of chloroximes 10 with N-Boc-Δ
3
-pyrroline 11 under conventional 
reaction conditions at room temperature. 
a








3.3.2.2.Conventional heating and Microwave irradiation 
Taking in mind the results obtained, we optimized the reaction conditions 
using chloroxime 10a as a model substrate. When the reaction was carried out 
under conventional heating by refluxing in EtOAc, the yield was comparable 
to that obtained at room temperature (Table 1.2, entry 1 vs Table 1.1, entry a), 
but reaction time was reduced from 7 to 3 days and only 2 equiv of 10a were 
consumed. The yield can be further improved up to 51% by adding a small 
percentage of water (1% v/v) to the reaction medium (Table 1.2, entry 2). 
Entry R equiv. of 10
a





a Ph 4 7 EtOAc 40 
b p-NO2-Ph 4 7 EtOAc 28 
c p-CH3O-Ph 4 7 EtOAc 45 
d Bn 4 7 EtOAc 32 
e p-NO2-Bn 4 7 EtOAc  2 





Chapter 3: Chemistry                                                                                                   a 
- 44 - 
 
 
entry equiv of 10a
a
 solvent time (h) T (°C) yield
d
 (%) 
1 2.0 EtOAc 72 reflux
b 
42 
2 2.0 EtOAc + H2O (1%) 72 reflux
b
 51 
3 1.5 EtOAc 2 x 0.5 80
c 
35 
4 2.0 EtOAc 3 x 0.5 80
c
 48 
5 2.5 EtOAc 4 x 0.5 80
c
 41 
6 3.0 EtOAc 5 x 0.5 80
c
 34 
7 2.0 EtOAc + H2O (1%) 3 x 0.5 80
c
 66 
8 2.0 EtOAc + H2O (2%) 3 x 0.5 80
c
 47 
9 2.0 EtOAc + H2O (1%) 3 x 0.5 90
c
 56 
10 2.0 EtOAc + H2O (1%) 3 x 0.5 100
c
 44 
TABLE 1.2. Optimization of reaction conditions for the cycloaddition of chloroxime 10a 
(R=Ph) to N-Boc-Δ
3
-pyrroline 11, under conventional heating or microwave irradiation 
.
a








The potential usefulness of the microwave-assisted methodology was then 
investigated, varying the reaction conditions, i.e., the number of equivalents of 
10a, time, temperature, and percentage of added water, with the aim of fine-
tuning the best reaction conditions (Table 1.2). The use of solid NaHCO3 (4 
equiv) as a base was kept as a constant in all the experiments. Heating cycles 
of 30 min each were applied. The first equivalent of chloroxime was added at 
the beginning of the experiment, and further 0.5 equiv portions were added 
before every additional heating cycle, since monitoring by TLC showed the 
presence of unreacted alkene 11, while chloroxime 10a was completely 
consumed. The highest yield was obtained after the addition of 2 equiv of 
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As observed under conventional heating conditions, the addition of a small 
percentage of water (1%v/v) to the reaction medium had a positive effect on 
the reaction outcome (Table 1.2, entry 7 vs 4). Thus, we selected as optimal 
conditions those reported in entry 7. While operating under these conditions, 
we extended our procedure to a series of differently substituted chloroximes. 
The data reported in Table 1.3 demonstrate that this methodology is versatile 
and can be fruitfully applied to the synthesis of a series of 3-substituted 

















Notably, the reaction time was significantly reduced from 7 days (at room 
temperature) or 3 days (refluxing under conventional heating) to 1.5h, and 
very importantly, the outcome of the reaction was not anymore dependent on 






 R time (h) yield
b 
1 Ph 3 x 0.5 66 
2 p-NO2Ph 3 x 0.5 60 
3 p-CH3OPh 3 x 0.5 67 
4 Bn 3 x 0.5 50 
5 p-NO2Bn 3 x 0.5 47 
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3.3.2.3. Continuous-flow technique 
The main limitation of the microwave methodology is, however, related to 
the possibility of scaling up the reaction. In fact, microwave devices 
commonly available in a research laboratory are designed to fit 0.2-35 mL 
sealed tubes, allowing performance of the reaction up to a maximum total 
volume of 25 mL. This entails the need to repeat the reaction several times in 
order to produce the desired cycloadduct in multigram scale. Moreover, as 
pointed out above, the procedure, albeit optimized, requires multiple operator 
interventions to add additional aliquots of chloroxime over time.  
Thus, we decided to investigate the feasibility of this type of cycloaddition 
reaction under continuous-flow conditions.
105,106
 For this purpose, we used the 
R2+/R4 flow system commercially available from Vapourtec (Figure 3.2). 
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Initially, the reaction was performed using a 0.25 M solution of 11 (0.25 
mmol) in EtOAc (1 mL) and an equimolar solution of chloroxime 10a (Table 
1.4, entry 1). The solutions were introduced into the flow stream (EtOAc) 
through two injection loops, mixing was achieved with a simpleT-piece, and 
the combined output was then directed through a glass column containing the 





Figure 3.3. Schematic representation of the cycloaddition reaction in flow. 
 
First, we chose the appropriate base among a selection of polymer-
supported (PS) bases (i.e., PS-sodium carbonate, Amberlyst A-21, PS-DBU), 
as well as solid NaHCO3 and K2CO3. All of the PS-bases turned out to be 
inefficient in the cycloaddition reaction, since the product 12 was isolated in 
unacceptable yield (<10%). Only solid K2CO3 gave a good result (50% yield), 
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The total flow rate was set in a way that the residence time of the reagents 
in the column was 30 min. The final flow line was then collected and 
evaporated to give the crude material, which was purified by column 
chromatography. A positive system pressure was maintained by using an in-
line 100 psi back-pressure regulator. 
 
Entry










1 1.0 80 30 50 
2 1.5 80 30 60 
3 2.0 80 30 63 
4 1.5 80 10 45 
5 1.5 90 10 69 
6 4.5 90 10 87 
7 1.5 100
d
 10 45 
TABLE 1.4. Cycloaddition of chloroxime 10a (R=Ph) to N-Boc-Δ
3
-pyrroline 11 under 
continuous-flow conditions
 a
Reactions conducted on a 0.25 mmol scale of N-Boc-Δ
3
-
pyrroline 11 in EtOAc (0.25 M solution), using solid K2CO3 as a base (4.0 equiv). 
b
All 




A further increase in the 
temperature up to 130 °Causes a dramatic reduction of the yield (8%). 
 
As shown in Table 1.4, under continuous-flow conditions it was possible to 
obtain cycloadduct 12a in good yield (69%, entry 5) in only 10 min using 1.5 
equiv of chloroxime 10a. This represents a significant improvement over the 
above described microwave-assisted methodology, since the reaction time was 
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yield (69% vs 66%). However, increasing the temperature to 100 °C was 
detrimental for the reaction yield (Table 1.4, entry 7 vs 5). 
Moreover, using a larger excess of chloroxime 10a (entry 6), complete 
conversion of the alkene was observed, and the yield was improved to 87%, 
but the isolation of the product was hampered by the presence of a large 
amount of furoxan and other byproducts and required intensive and time-
consuming purifications by column chromatography. Therefore, we selected 
the conditions reported in Table 1.4, entry 5 as the optimal ones and validated 
our synthetic protocol by applying such optimized conditions to the series of 
chloroximes 10a-c and 10h-j. In all cases (Table 1.5), the cycloadducts were 
obtained in good yield (60-73%), very short time (10 min), and using as low as 






 R time (min) Yield
b
 (%) 
1 Ph 10 69 
2 p-NO2-Ph 10 60 
3 p-CH3O-Ph 10 73 
4 Bn 10 71 
5 p-NO2-Bn 10 67 
6 p-CH3O-Bn 10 74 
TABLE 1.5. Cycloaddition of chloroxime 10a-c and 10h-j to N-Boc-Δ
3
-pyrroline 11 under 
continuous-flow conditions
 a
Results obtained using the optimized conditions reported in 




Moreover, this process could be easily scaled up by simply letting the 
instrument run for longer time and using a larger base-containing column, 
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3.3.3. Synthesis of compounds 6a-l 
As previously reported, running the 1,3-dipolar cycloaddition reaction 
under continuous-flow conditions resulted in an straightforward generation of 
the N-Boc-protected bicyclic-Δ
2
-isoxazolines 12. Removal of the N-Boc group 
with 4 M HCl solution in dioxane and subsequent methylation with methyl 
iodide in acetone produced derivatives 6a-d, 6h-j, and 6l. The carboxylic acid 
derivative 6e was obtained by deprotecting the t-butyl ester 6l with 
trifluoracetic acid at room temperature. Cleavage of the tosylate group of 6d 
with NaOH in EtOH afforded derivative 6g. Finally, reduction with zinc 
powder in acetic acid converted the nitro-substituted compounds 6b and 6i 
into the corresponding amino derivatives 6f and 6k, respectively (Scheme 3.4). 
 
Scheme 3.4. Reagents and conditions: (a) R2+/R4 flow reactor, EtOAc, K2CO3, 80 °C, 10 
min (60-73%); (b) 4N HCl, dioxane, room temperature, 1 h (99%); (c) CH3I, K2CO3, acetone, 
room temperature, 12 h (31-45%); (d) TFA/CH2Cl2 1:3, room temperature, overnight (99%); 
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3.4. Synthesis of “bisubstrate” DNMT1 inhibitors 
Once that the biological investigation of the first two series of compound 
was completed (Chapter 4) and being interested in the development of 
analogues endowed with improved enzyme binding properties and higher 
inhibitory potency, we decided to synthesize new, longer compounds, obtained 
by the combination of the SAM-competitive isoxazoline scaffold with 
“warheads” targeting the nucleotide binding site (i.e. a portion of the well-
known DNMT1 inhibitor SGI-1027), as bisubstrate inhibitors of DNMT1 
(Figure 3.4).  
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3.4.1. Synthesis of pyrimidinic building blocks 
Acids 25-27 were straightforwardly obtained in high yield reacting 4-chloro 
pyridine derivatives 22-24 and p-aminobenzoic acid, according the procedure 





Scheme 3.5. Reactions and conditions: (a) MW, 2-propanol, 120 °C, 30 min/1.5 h (90-99%) 
 
3.4.2. Synthesis of final compounds (16-21) 
The mesylate derivatives 9a-b, prepared as previously described, were 
reacted with sodium azide in dimethylformamide to afford azides 14a-b. 
These were treated with triphenylphosphine in wet methanol to afford the 
corresponding amines 15a-b. Then, derivatives 16a-b, 17a-b and 18a-b were 
prepared by amide coupling reaction between amines 15a-b and acids 25-27, 
under the standard HBTU/HOBt/DIEA conditions. However, since the amide 
coupling reaction was slow and gave only low yields (up to 10%) of 19a-b, we 
resolved to protect the two amino groups and prepare acetyl derivative 24 
(Scheme 3.5). Thus, using this protected derivative, coupling reaction with 
amines 15a-b gave in good yield derivatives 18a-b.  
For the synthesis of derivatives of type 20 and 21, amines 15a-b were 
treated under microwave irradiation with the appropriate 4-chloro pyrimidine 
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Scheme 3.6. Reactions and conditions: (a) MsCl, TEA, CH2Cl2, 0 °C to room temperature, 
45 min (99%); (b) NaN3, DMF, reflux, 3h (90%); (c) PPh3,MeOH/H2O 1:1, room temperature, 
30 min (73-82%); (d) HOBt, HBtU, DIEA, THF/DMF 3:1, room temperature, 1-12h (68-
80%); (e) DCM/TFA 9:1, room temperature, 30 min (99%); (f) NaOH 1N, EtOH, room 
temperature to reflux, 2h (43-70%); (g) MW, 2-propanol, 180 °C, 30 min (67-80%). 
 
The carboxylic acid derivatives 16c, 17c, 20c and 21c were obtained by 
deprotecting the t-butyl esters 16b, 17b, 20b and 21b, respectively, with 
trifluoracetic acid at room temperature. Finally, treating derivative 18a in 
methanol with 1N aqueous solution of NaOH, deprotected compound 19a was 
obtained. When these reaction conditions were applied on derivative 18b, 
formation of both t-butyl ester 19b and the corresponding acid 19c was 
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3.5. Virtual screening: a new approach for the discovery of DNMT1 
inhibitors 
Until now, most compounds associated with DNA methylation inhibition 
have been identified fortuitously, and even fewer have been validated as 
directly targeting DNMTs in vitro or in vivo. Limited studies have been 
reported thus far to explore systematically the DNMT inhibition properties of 
large compound databases. Experimental characterization of hundreds or 
thousands of small molecules as demethylating agents would be a daunting 
task in terms of cost and time. To accelerate systematic screening, 
computational techniques, including virtual screening, are increasingly being 
used to identify active compounds.
86 
In 2011, in collaboration with Prof. Jose Medina-Franco (Torrey Pines 
Institute for Molecular Studies, Florida, United States), 260,000 compounds in 
the Diversity Set available from the National Cancer Institute (NCI; 
http://dtp.nci.nih.gov/) were the starting point to identify additional DNMT1 
inhibitors. Six of the top scoring compounds (Figure 3.5) were synthesized by 
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3.5.1. Synthesis of NSC201299 (30) 
For the preparation of derivative 29, the well-known Fischer indole 
synthesis
109
starting from the symmetrical diethyl 4-oxopimelate was chosen. 
In order to obtain the indolic scaffold, a two-step procedure, taking advantage 
of the smooth formation of pyridazinone 28, followed by treatment with 
saturated HCl/MeOH solution at reflux, proved to be efficient (73% overall 
yield).
110





Scheme 3.7. Reactions and conditions: (a) diethyl-4-oxopimelate, toluene, reflux, 48h 
(90%); (b) HCl/MeOH, reflux, 24h (80%); (c) NaOH 1N, MeOH, room temperature, 3h 
(99%). 
 
3.5.2. Synthesis of NSC30727 (34) 
The 2-amino-5-oxo-5-(p-tolyl)pentanoic acid 34 was obtained exploiting a 
five-step procedure, as depicted in Scheme 3.8. The first step was a nucleofilic 
substitution, followed by protection and deprotection of the amino and 





Scheme 3.8. Reactions and conditions: (a) DIPEA, DMPU, BuLi, THF dry, -78 °C, 2h; 
(b) HCl 2N, Et2O, room temperature, 1h (60%); (c) Acetic anhydride, CH2Cl2, room 
temperature, 4h (99%); (d) Amb. 900 OH, EtOH/H2O, room temperature, 3h; (e) HCl 1N, 
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3.5.3. Synthesis of NSC626939 (38) and NSC627216 (41) 
The sulfonamides 35 and 39 were obtained by reaction between 4-
nitrobenzene-1-sulfonyl chloride and secondary amines. The nitro group was 
promptly reduced to the key intermediates 36 and 40 by heterogeneous 
catalytic (palladium/activated carbon) hydrogenation. The reaction of this 
compounds with 4-methoxybenzoyl chloride in dry THF, or with benzoyl 
chloride in THF/H2O gave the corresponding derivatives 37 and 41. The 
subsequent hydrolysis of 37 with aqueous lithium hydroxide in methanol 










Scheme 3.9. Reactions and conditions: (a) Gly-OMe HCl, TEA, dry CH2Cl2, room 
temperature, 1.5h (57%); (b) H2, Pd/C, EtOH, room temperature, 2h (99%); (c) 4-
methoxybenzoyl chloride, TEA,  dry THF, room temperature, 12h (77%); (d) LiOH, 
H2O/MeOH, room temperature, 2.5h (90%); (e) -Ala, NaOH 1N, room temperature, 3h 
(37%); (f) benzoyl chloride, NaHCO3, THF/H2O, reflux, 48h (70%).   
 
3.5.4. Synthesis of NSC97155 (45) 
Compound 43 was synthesized by treating N-ethoxycarbonylphthalimide 
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subsequent amidation and hydrolysis gave the final compound 45 in short time 





Scheme 3.10. Reactions and conditions: (a) SOCl2, MeOH, room temperature, 30 min (99%); 
(b) N-ethoxycarbonylphthalimide, Na2CO3, H2O, from 0 °C to room temperature, 1h (99%); 
(c) isobutyl chloroformate, NMM, NH3, THF, room temperature, 1.5h (51%); (d) HCl 2N, 
dioxane, room temperature, overnight (99%). 
 
3.5.5. Synthesis of NSC140052 (48) 
The first step in the synthesis of pyrrolo[3,4-d]-pyrimidine 48 was carried 
out by the addition of the sodium salt of -aminobutyric acid to ethyl acrylate 
in absolute ethanol. Condensation of this intermediate with ethyl oxalate in the 
presence of sodium ethoxide gave derivative 46 in moderate yield. Finally, the 
benzilidene derivative 47, obtained by acid-catalyzed condensation of 46 with 
4-chlorobenzaldehyde, was subjected to addiction of guanidine in order to 




Scheme 3.11. Reactions and conditions: (a) NaOEt, ethyl acrylate, EtOH, from 0 °C to room 
temperature, 12h; (b) NaOEt, diethyl oxalate, 80 °C, 3h (52%); (c) 4-chlorobenzaldehyde, 
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3.6. From NSC140052 to novel pyrrolo[3,4-d]-pyrimidines: new DNMT1 
inhibitors (51a-h) 
As emerged from the biological assays (Chapter 4), in the series of 
derivatives found via virtual screening, NSC140052 resulted the most 
powerful compound, showing a good inhibitory activity against DNMT1 (IC50 
= 220 µM).  
Being interested in the synthesis of new small molecule derivatives of this 
new hit, and taking advantage of its synthetic procedure previously described, 
we developed a small library of compounds characterized by several 
functional groups on the aromatic ring (-OCH3, -COOH, -Cl) and different 
length of the side chain (from 2 to 4 carbon atoms) as shown in Scheme 3.12. 
 
 Scheme 3.12. Reactions and conditions: (a) NaOEt, ethyl acrylate, EtOH, from 0 °C to room 
temperature, 12h; (b) NaOEt, diethyl oxalate, 80 °C, 3h (52-66%); (c) Aldehydes, HCOOH, 
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3.7. Six months abroad: Microwave and Continuous-flow chemistry in the 
lab of Prof. C. O. Kappe 
Once that the potency of microwave and flow techniques was validated in 
the field of 1,3-dipolar cycloaddition, and with the aim to improve my 
knowledge in this fields, I‟ve been for six months at the Karl-Franzens-
Universität, Graz, Austria, in the laboratory of Prof. C. O. Kappe.  
 
3.7.1. Background & Aim of the work 
High-temperature chemistry offers many distinct benefits, as demonstrated 
by the recent success of microwave-assisted organic synthesis.
113
The short 
reaction times experienced in microwave chemistry protocols form an ideal 
basis for continuous flow processing, where short residence times are essential 
in order to achieve a high throughput.  
Starting from this background, we planned and realized an extension of this 
concept, demonstrating that conditions optimized using batch microwave 
system on a milliliter scale can be translated to a laboratory-scale microreactor 
setting, and can be further adapted to a mesofluidic flow regime that allows a 
L/h throughput, therefore more closely resembling pilot-plant/production-scale 
capabilities (Figure 3.6).  
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As model systems, we evaluated different continuous flow strategies for the 
generation of the anti-inflammatory drug nabumetone [4-(6-methoxy-2-
naphthalenyl)-2-butanone] and related 4-aryl-2-butanones using a combination 
of two process-intensified flow reaction steps. The synthetic routes were first 
optimized on small scale using controlled microwave batch technology and 
then translated to continuous flow processes. Ultimately, a custom built large-
scale mesofluidic flow setup capable of processing 2.7 L/h was designed to 




3.7.2. Planned synthesis of derivatives 53a-c 
Some of the most efficient general published methods for synthesizing 4-
aryl-2-butanones 53a-c are summarized in Scheme 3.13. All three protocols 
(Mizoroki-Heck, Wittig, and aldol reactions) involve the initial preparation of 
the corresponding 4-aryl-3-buten-2-ones 52a-c which is then followed by 
selective hydrogenation of the C=C double bond to 4-aryl-2-butanones 53a-c.  
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With the aim of developing process-intensified methods for the rapid 
synthesis of the key intermediates 52a-c in a flow format, we have initially 
optimized the above transformations under microwave batch conditions and 
then adapted for use in a flow reactor. The final hydrogenation was achieved 
in a commercially available flow hydrogenation device (H-Cube).  
 
3.7.3. Mizoroki-Heck reaction 
The starting point for our studies involved the adaptation of the Mizoroki-
Heck reaction of methyl vinyl ketone (MVK) with 4-iodoanisol (54b) into a 













 t [min] 










1 MW  1 1.1 160/20 - > 99 60 
2 MW  1 1.5 160/20 - > 99 72 (74)d 
3 MW  0.5 1.5 160/20 - >  99 70 
4
 MW  0.2 1.5 160/20 - >  99 74 (76)d 
5 MW  0.1 1.5 160/20 - 84 57 
6 MW  0.2 1.5 180/10 - >  99 69 (66)d 
7 flow 0.2 1.5 180/10 1.6 >  99 73 (67)
d 
TABLE 1.6. Optimization of the MizorokiHeck reaction of 4-iodoanisole (54b) and methyl 
vinyl ketone (MVK) under microwave batch and continuous flow conditions.
 a 
General 
conditions: 0.4 mmol 54b, Cs2CO3 (1.1 equiv), DMF/H2O 3:1 (3 mL); single-mode 
microwave irradiation (IR temp monitoring). Flow experiments (60 bars pressure) were 
performed using a ThalesNano X-Cube Flash instrument equipped with a 16 mL stainless steel 
coil. 
b 
Conversions refer to HPLC peak area integration at 230 nm.
 c 
Product purity refers to 
relative peak area (%) ratios of crude HPLC traces. 
d 
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In our hands, the Mizoroki-Heck coupling proceeded well under controlled 
microwave conditions. Special attention was paid to the selection of a proper 
base for this transformation (Cs2CO3), keeping the general requirement for 
homogeneous reaction conditions for subsequent translation to a continuous 
flow process in mind. After different experiments, we were able to identify the 
optimal set of conditions which worked best in a small-scale microwave batch 
environment (Table 1.6, entry 6), and that could be applied to the flow-
chemistry apparatus.  
Continuous-flow experimentation was performed in a high-temperature, 
high-pressure microtubular flow unit that can be used for processing 
homogeneous reaction mixtures (X-Cube Flash, Thales Nanotechnology Inc.). 
Although the successful results (67% isolated yield), due to the comparatively 
low selectivity achieved in this Mizoroki-Heck coupling and the required 
product purification of the crude reaction mixture, and in consideration of the 
high costs of catalyst and starting materials (aryl-iodides) it was decided not to 
further pursue this avenue on scale. 
 
3.7.4. Wittig reaction 
As a second synthetic strategy to access the key intermediates 52a-c, the 
Wittig olefination of aldehydes 55a-c in the presence of 
(acetylmethylene)triphenylphosphorane (56) was investigated (Scheme 3.13). 
In our hands, employing aldehyde 55b and phosphorane 56 in MeCN or DMF 
at temperatures of 190-210 °C, high conversions were achieved under 
microwave conditions within 10-20 min (Table 1.7). 
Although MeCN behaved well as solvent, truly homogeneous reaction 
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Therefore, the conditions reported in Table 1.7, entry 6 were selected as 
optimal conditions for both batch and continuous flow processing and was also 
applied to the synthesis of 52a and 52c, providing the desired products in high 











1 MW   1.5 190/20 MeCN 94 
2 MW   1.5 200/20 MeCN 98 
3 MW   1.7 200/20 MeCN 100 (94)c 
  4
d MW   1.7 200/20 DMF 97 
  5
d
 MW   1.7 210/20 DMF 99 (95)c 
6
d
 MW   1.7 210/10 DMF 99 (96)c 
7
e flow  1.7 210/10 DMF 99 (97) 
TABLE 1.7. Reaction optimization for the Wittig reaction of p-anisaldehyde (55b) and 
(acetylmethylene)triphenylphosphorane (56) under microwave batch and continuous flow 
conditions.
 a
General conditions: 0.4 mmol 55b, 1.5-1.7 equiv 56, 3 mL of solvent, single-
mode microwave irradiation, IR temperature control. 
b
HPLC peak area integration at 230 nm. 
c
Isolated yields using flash chromatography. 
d
Homogeneous reaction conditions. 
e
Flow 
experiments were performed in a Uniqsis FlowSyn™ instrument using a 10 mL stainless steel 
coil (55b, 0.1 M). 
 
Nevertheless, from the standpoint of process chemistry, the use of an 
expensive organophosphorous reagent (atom economy), and the generation of 
stoichiometric amounts of triphenylphosphine oxide byproduct are clearly not 
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3.7.5. Aldol reaction 
In view of our interest to develop economic and efficient synthetic 
strategies for the preparation of 53a-c on an industrial scale, we focused our 
attention on the aldol route (Scheme 3.13), which apart from the readily 
available aryl aldehyde precursors 55a-c only requires acetone and an 
inorganic base as starting materials.
116, 117
 
Employing p-anisaldehyde, full conversion was achieved using 0.06 equiv 






















































TABLE 1.8. Reaction optimization for the aldol reaction of acetone with aldehydes 55a-c 
under microwave batch and continuous flow conditions.
 a 
General reaction conditions: 55a-c 
(0.1-0.8 M), NaOH (0.06 equiv), acetone/water 2:1. Batch experiments were carried out using 
a single-mode instrument (IR temperature sensor). Flow experimentation was performed in a 
Uniqsis FlowSyn™ device. 
b
 HPLC peak area integration at 230 nm.
c 
Isolated yield after flash 
chromatography. 
d
 10 mL stainless steel coil. 
e
 5 mL stainless steel coil. 
f 
2 equiv of NaOH, 
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Applying these conditions to the flow reactor system, we initially 
performed the aldol reaction using a 5-mL stainless steel reaction coil, a 5 
mL/min flow rate (1 min residence time), and 120 °C temperature. As the 
aldol condensation proceeds also very slowly at room temperature, freshly 
prepared reaction mixtures were used. For the synthesis of 52a and 52c a 10-
mL stainless steel coil in combination with a 1.34 mL/min flow rate was 
utilized to ensure the required residence time of 450 s at 70 °C. In the case of 
naphthylaldehyde 55a the concentration had to be lowered to 0.1 M because of 
solubility issues. Nevertheless, full conversion and a high isolated yield of the 
corresponding aldol condensation product 52a was obtained (94%).  
 
3.7.6. Large-scale flow aldol condensation 
In order to demonstrate the scalability of the flow reaction conditions 
obtained in a laboratory-scale microreactor using steel coils of 5-10 mL 
internal volume to larger scales more similar to those used in a pilot or 
production setting we have additionally performed the aldol condensation of 
p-anisaldehyde and acetone shown in Table 1.8 in a mesofluidic flow setup, in 
collaboration with Microinnova Engineering (Graz, Austria) (Figure 3.7).  
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The feed module consists of a microannular gear pump, a Coriflow mass 
flow meter and a piezosensitive pressure sensor. On the other hand, the 
reaction module consists of a Teflon residence time tubing (∼1 m length), 
situated in a silicon oil bath, with 8 mm inner diameter and filled with Teflon 
mixing elements, in addition to a micro heat-exchanger and a pressure 
maintaining valve. The overall flow rate in the experiments was 2.4 kg/h, 
which corresponds to a product flow of 0.35 kg/h. In 104 min, 4.65 L reaction 
mixture were processed at 120 °C: starting from 0.54 kg of aldehyde, we 
recovered 0.67 kg of product, without further purifications! 
 
3.7.7. The final step: continuous flow hydrogenation 
For the selective reduction of the double bond in 4-aryl-3-buten-2-ones, we 
have investigated a continuous-flow hydrogenation protocol employing a 
fixed-bed catalyst (H-Cube, Thales Nanotechnology Inc.).
118
 The flow 
hydrogenation of model substrate 52b was initially optimized using Ra/Ni 
cartridge, as it provided high selectivity for the double-bond hydrogenation at 
room temperature.  
Having established the optimum flow hydrogenation conditions for the 
model substrate, we were interested in investigating the synthesis of the other 
compounds. Although our initial flow experiments involved EtOH as the 
solvent, the comparatively low solubility of 52b and 52c led us to utilize DMF 
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52a DMF 0.5 1 100 > 99 90 
52b EtOH 0.5 1.5 25 > 99 94 
52c DMF 0.7 1 35 > 99 91 
Table 1.9. Optimized reaction conditions for the flow hydrogenation of 4-aryl-3-buten-2-
ones 5a-c.
a
 H-Cube, Full-H2 mode at atmospheric pressure, substrate in EtOH or DMF, 30  4 
mm i.d. catalyst cartridge, ~150 mg catalyst. 
b 
Determined by GC/MS (peak area %). 
c 
Isolated 
product yield after flash chromatography. 
 
In summary, using the synthesis of 4-aryl-2-butanones 53a-c as model 
transformations, we have demonstrated that small scale microwave batch 
processing is a useful tool to optimize reaction conditions for achieving high 
product yields and selectivities in the shortest possible reaction times. The 
resulting time-temperature histories were easily translated to conventionally 
heated high-temperature continuous flow reactors using 1000 μm stainless 
steel coils. Because of the high surface-to-volume ratio in these type of 
microreactors, rapid heat transfer to and from the reaction mixture can be 
attained, therefore closely mimicking the situation of a small scale microwave 
experiment. Using appropriate static mixers in connection with a mesofluidic 
tubular reactor, the conditions obtained from laboratory scale instruments can 
be directly scaled by a factor of ∼10 without reoptimization of conditions. As 
demonstrated for the synthesis of 4-(4-methoxyphenyl)-3-buten-2-one (52b), a 
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4.1. Biological evaluation of 
2
-isoxazoline derivatives 
All the biological assays have been performed by Prof. Frank Lyko, Prof. 
Dirk Kuck (Division of Epigenetics, German Cancer Research Center, 
Heidelberg, Germany) and Reaction Biology Corp. ("RBC", Malvern, 
Pennsylvania, USA). 
 
4.1.1 Inhibitory activities against DNMT1 
To date, there is no standardized biochemical assay available that delivers 
reliable data of the enzymatic activity of DNMTs. Recently, Kuck et al.
83
 
established a biochemical in vitro methylation assay using recombinant 
DNMT1, isolated and purified from Sf9 insect cells (derived from Spodoptera 
frugiperda). Tritium labeled S-adenosylmethionine (SAM) was used as methyl 
group donor, and the incorporation of radioactivity was quantitated by a 
scintillation counter. 
In accordance with previous reported data by our research group,
98
 a 
preliminary screening of the activity of compounds 5a-l and 6a-l at the single 
concentration of 2 mM was performed, using procaine, RG108, and S-
adenosylhomocysteine (SAH) as reference compounds (2 mM DMSO 
solution). Procaine (as well as procainamide) was reported to inhibit DNMT 
activity at high drug concentrations. In addition, the assay sensitivity required 
comparably high concentrations (500 nM) of enzyme and, consequently, high 
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5f p-NH2-Ph 20.2 0.28 
5g p-OH-Ph 88.0 0.37 



















































 - 0.5 0.01 
TABLE 4.1. Biochemical DNMT assay of compounds 5a-k and 6a-k against hDNMT1
. a
The 
relative enzymatic activity (in percent) is shown as the mean value of three measurements. 
b





and SAH were used as reference compounds. All compounds were tested in a concentration of 
2 mM against 500 nM of DNMT1. Compounds with an inhibition greater than 20% were 
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Even if accurate structure-activity relationships could not be derived from 
this assay, a few empirical considerations could be drawn pointing at the 
identification of potential inhibitors and to rule out inactive compounds.  
It is noticeable that while both procaine and RG108 were inactive in this 
assay, a number of tested compounds show a clear-cut inhibition of the 
enzyme activity (Table 4.1), particularly when a nitro- or an amino- group is 
present as a substituent of the benzene ring (compounds 5b, 5f, 5i, 5k and 6b, 
6f, 6i, 6k). Indeed, at the tested concentration, these compounds reduced the 
activity of DNMT1 at a very low level (0.3% in the case of 5b, Table 4.1), a 
particularly significant outcome for non-nucleosidic inhibitors.  
Similarly to what we previously reported for their oxazolino analogues,1 
nitro-substituted isoxazolines derivatives seem to be more active than their 
amino- counterparts (nearly 70-fold in the case of compounds 5b and 5f, Table 
4.1), but this become less evident (nearly 2-fold) when the phenyl ring linked 
to the heterocycles is replaced by a benzyl moiety (compare the inhibition 
elicited by compounds 5b and 5f with those elicited by 5i and 5k, 
respectively). It is noteworthy that quite an opposite trend is observed in the 
case of bicyclic derivatives 6. In fact, the nitrophenyl-substituted 
pyrrolidinoisoxazoline 6b is 6-fold less active than its aminophenyl- 
counterpart (Table 4.1), whereas the activities of the benzylic analogues 6j and 
6k are comparable. In a similar way, the introduction of the methoxy group 
produced active derivatives only in the case of phenyl-substituted isoxazolines 
(compound 5c) and benzyl-substituted pyrrolidinoisoxazolines (compound 6j), 
whereas the corresponding benzyl- and phenyl- analogues (compounds 5j and 
6c, respectively) were inactive.  
Following the above considerations, we then selected derivatives 5b, 5f, 5i, 
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assay to generate curves from which the corresponding IC50 values were 
obtained (Figure 4.1).  
 
 
Figure 4.1. Dose–response plots for selected compounds 5b, 5f, 5i, 6f, 6i, and 6j against 
DNMT1. The IC50 concentrations of selected compounds were determined by biochemical 
DNMT assays under identical conditions (500 nM enzyme, 0.7 M AdoMet, 400 nM 
hemimethylated oligo). Each data point represents the mean ± SD of three measurements, and 
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In agreement with results in Table 4.1, the nitrophenyl isoxazoline 5b 
showed the highest inhibition of DNMT1 with an IC50 value of 150 μM, 
whereas its amino- counterpart 5f as well as the aminophenyl- and the 
nitrobenzyl-substituted pyrrolidinoisoxazolines 6f and 6j were 2- to 4-fold less 
potent (IC50 values of 270, 570, and 310 μM, respectively). Both the 
nitrobenzyl isoxazolines 5j and the methoxybenzyl pyrrolidinoisoxazoline 6k 
were consistently less active (IC50 values of 1600 and 1130 μM, respectively). 
SAH was used as a nonspecific positive control and confirmed its efficient 
inhibition of DNMT1 (IC50 of 4 μM, dose-response curve not shown). 
 
4.1.2. Competition assays 
As derivative 5b emerged as the most promising candidate for further 
development, we decided to gain a better understanding of the kinetic 
mechanism(s) for the observed inhibition of DNMT1. Because mutational 
analyses are long-lasting and may affect the enzyme conformation, we applied 
a simple method reported by Lai and Wu for assessing the mode of 
inhibition.
119
 According to this method, the mode of inhibition can be 
evaluated by holding the inhibitor constant at its IC50 concentration and 
varying the substrates. The behavior of the curves obtained under these 
conditions will point to the mode of inhibition. For DNMTs, these substrates 
are the methyl group donor SAM and the DNA (represented by a short oligo) 
and each of them binds to its distinct binding site in the catalytic domain of 
DNMT1.  
Therefore, the concentration of 5b was kept constant at 150 μM (IC50 value, 
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It can be seen that increasing the SAM concentration can nearly completely 
relieve the enzyme inhibition, whereas this is not affected by increasing the 
oligo substrate (Figure 4.2).  
According to the model,
119
 this is consistent with an inhibitor that is 
competitive with respect to SAM and noncompetitive with respect to the oligo. 
 
 
Figure 4.2 Derivative 5b competes with the SAM binding site. The catalytic domain of 
DNMT1 has two binding sites, one for the oligo substrate and one for the SAM substrate. A 
modified biochemical DNMT activity assay was established to determine the mode of action 
of 5b. Competition experiments were performed by increasing the concentration of the oligo 
substrate (oligo varied) or, alternatively, the SAM substrate (SAM varied). The assay was 
performed under standard conditions; please note that DNMT1 concentration was always kept 
constant (500 nM) as well as the inhibitor (5b) concentration (150 μM). The initial enzymatic 
activity under standard conditions in presence of the inhibitor was defined as 100% inhibition 
before increasing substrate concentrations to look for competition events. According to the 
model of Lai and Wu (see text), 5b competes with SAM for the cofactor binding site but not 
for the oligo-binding site. 
 
Of note, these experiments represent one of the first efforts to elucidate 
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4.1.3. Inhibition of cell proliferation 
Finally, we explored the effect of compound 5b on the proliferation of 
HCT116 human colon carcinoma cell line. To this end, cells were incubated 
for 72h with increasing concentrations (300, 500, and 750 μM) of 5b in 
comparison to azacytidine (1 μM) or DMSO alone for control. The 
proliferation was assessed by counting viable cells after trypan blue staining. 
As shown in Figure 4.3, in these conditions compound 5b induces a strong and 
dose-dependent antiproliferative effect, with a GI50 value (the concentration of 
the compound that inhibits cell growth by 50%) of 360 μM.  
 
 
Figure 4.3. Derivative 5b induces a strong antiproliferative effect after 72h in HCT116 human 
colon carcinoma cells compared to DMSO treated cells. Azacytidine was included as a 
positive control. Ctrl are DMSO treated cells. GI50 value was determined by SigmaPlot 12.0 




 methylation assay 
In order to systematically characterize the demethylation responses after 5b 
treatment in HCT116 human cancer cell lines, a new methylation assay was 
used. In fact, in the last years, huge progress has been made in the 
development of array- or sequencing-based technologies for DNA methylation 
analysis. In particular, the Illumina Infinium
®
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BeadChip (Illumina Inc., CA, USA) allows the simultaneous quantitative 
monitoring of more than 480,000 CpG positions, offering the highest 
resolution for understanding methylation changes.
120
 Upon treatment with 
bisulfite, unmethylated cytosine bases are converted to uracil, while 
methylated cytosine bases remain unchanged. The assay interrogates these 
chemically differentiated loci using two site-specific probes, one designed for 
the methylated locus (M bead type) and another for the unmethylated locus (U 
bead type). Single-base extension of the probes incorporates a labeled di-
deoxy nucleoside triphosphate (ddNTP), which is subsequently stained with a 
fluorescence reagent. The level of methylation for the interrogated locus can 
be determined by calculating the ratio of the fluorescent signals from the 
methylated vs unmethylated sites.  
As shown in Figure 4.4., compound 5b is able to induce a reliable decrease 
in methylation of specific loci in HCT116 human colon carcinoma cells. On 
the basis of these findings, we proposed 5b as a novel lead compound for the 
development of non-nucleoside DNMT inhibitors. 
 
Figure 4.4. Illumina Infinium
®
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4.2. Biological evaluation of “bisubstrate” inhibitors 
As derivative 5b competes with SAM for the binding site, a proper 
derivatization of this scaffold could lead to longer “bisubstrate” inhibitors, 
able to occupy both DNA and SAM binding pockets. Docking studies as well 
as biological assays are ongoing to evaluate the potency of these new 
compounds in inhibiting the activity of DNMT1. Preliminary data show that 
some of them are 2 to 10 fold more effective than the lead compound in 
inhibiting the target (Figure 4.5). 
 
Figure 4.5. Comparison of the new molecules with the lead compound at 100 µM. Human 
DNMT1 with N-terminal GST tag, expressed in baculovirus expression system, 0.005 mg/ml 
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4.3. Biological evaluation of NCI lead-like set 
Taking advantage of a docking-based virtual screening approach with a 
validated homology model of DNMT1, six compounds of the NCI lead-like 
set were prepared and their inhibitory activity against DNMT1 was tested. 
Applying the same procedure developed for the isoxazoline derivatives, a 
preliminary screening of the activity of NSC compounds at the single 
concentration of 2 mM was performed.  
 
Figure 4.6. Biochemical DNMT assay of NSC compounds against hDNMT1. 
 
As shown in Figure 4.6, some derivatives emerged as the most promising 
candidates for further biological investigations. In fact, following the above 
considerations, we selected NSC140052, NSC201299 and NSC30727 among 
the most active compounds and carried out dose-response assay to generate 
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Figure 4.7. Dose–response plots for selected compounds against DNMT1. The IC50 
concentrations of selected compounds were determined by biochemical DNMT assays under 
identical conditions (500 nM enzyme, 0.7 M AdoMet, 400 nM hemimethylated oligo). Each 
data point represents the mean ± SD of three measurements, and the data were analyzed by 
SigmaPlot version 12.0. 
 
In agreement with results in Figure 4.6, the pyrrolo[3,4-d]-pyrimidine 
NSC140052 showed the highest inhibition of DNMT1 with an IC50 value of 
220 μM, whereas the 2-amino-5-oxo-5-(p-tolyl)pentanoic acid NSC30727 as 
well as the indole derivative NSC201299 were less potent (IC50 values of 980, 
and 700 μM, respectively). Starting from this findings, we proposed it as a hit 
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4.4. Biological evaluation of analogues of NSC140052 
As derivative NSC140052 resulted the most powerful compound of the 
series, we developed a small library of compounds characterized by several 
modifications of the hit. Docking studies as well as biological assays are 
ongoing to evaluate the potency of these new compounds in inhibiting the 
activity of DNMT1. Preliminary data show that the new derivatives with an 
acid group on the aromatic ring are 2 to 27 fold more active than the lead in 
inhibiting DNMT1 (Figure 4.8). 
 
Figure 4.8. Comparison of derivatives 51a-h with the lead compound at 1 mM. Human 
DNMT1 with N-terminal GST tag, expressed in baculovirus expression system, 0.005 mg/ml 
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5.1. Docking and binding mode of 
2
-isoxazoline derivatives 
On the basis of the results of the competition assay discussed above, the 
binding mode of 5b into the binding pocket of the cofactor of human DNMT1 
was analyzed using molecular modeling studies.  
Molecular docking and other computational approaches are increasingly 
being used to explore the ligand-binding interactions of DNMT inhibitors.
121
 
Until now, molecular modeling studies have been conducted using validated 
homology models of the methyltransferase domain of DNMT1.
86, 93 
However, 
a crystallographic structure of human DNMT1 has been recently published
122
 
which contains the methyltransferase domain bound to DNA-containing 
unmethylated CpG sites.  
On the basis of the experimental results of the competition assays, the 
binding of 5b into the binding site of the cofactor was further explored using 
molecular docking. Briefly, the R and S configurations of 5b in neutral and 
protonated forms (at the amino group) were flexibly docked into the 
crystallographic structure of the methyltransferase domain of human DNMT1 
using Glide Extra Precision (XP), version 5.7.
123
  
The calculated docking scores of the R and S configurations of 5b in 
protonated form were -4.0 and -3.5 kcal/mol, respectively. The docking score 
of the neutral form of each configuration was -3.0 kcal/mol. These results 
suggest that 5b binds to the cofactor binding site in the protonated form. The 
docking scores of 5b were higher, i.e. less favorable, than the calculated 
docking score for SAH, which was -7.6 kcal/mol. The docking scores are in 
agreement with the results of the experimental DNMT1 inhibition assays, 
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Figure 5.1. (A) Comparison of the binding modes of the R (green) and S (yellow) 
configurations of 5b predicted by Glide. Crystallographic SAH (gray) is shown as reference. 
Hydrogen bonds for R-5b are displayed as magenta dashes. Selected amino acids residues 
within 4.5 Å of 5b are shown. Nonpolar hydrogen atoms are omitted for clarity. (B) Two 
dimensional interaction map displaying amino acid residues within 4.5 Å of R-5b. The 
ligand proximity contour is depicted with a dotted line. The ligand solvent exposure is 
represented with blue circles; larger and darker circles on ligand atoms indicate more solvent 
exposure. The receptor solvent exposure differences, in the presence and absence of the 
ligand, are represented by the size and intensity of the turquoise discs surrounding the 
residues; larger and darker discs indicate residues highly exposed to solvent in the active site 
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Figure 5.1A shows a tridimensional binding model of the protonated R and 
S configurations (carbon atoms in green and yellow, respectively). The 
structure of co-crystallized SAH is shown as a reference (carbon atoms in 
gray). Together with the comparable docking energies calculated for the two 
configurations (see above), this hints that both enantiomers have similar 
enzymatic inhibitory activity.  
A two-dimensional representation of the binding mode of R-5b is shown in 
Figure 5.1B. According to the derived docking model, 5b occupies the binding 
site of the cofactor which is created by residues from the motifs I-III and X of 
the methyltransferase domain.
124
 Compound 5b binds in the region where the 
L-homocysteine and ribose moieties of SAH bind. The Δ
2
-isoxazoline ring 
makes contacts with the side chain of Asn1578 and the backbone of Phe1145. 
The phenyl rings makes hydrophobic interactions mainly with Gly1147, 
Gly1223, Ala1579, and the backbone atoms of Ser1146 and Asn1578. The 
positively charged amino group forms a hydrogen bond with the side chain of 
Glu1168, which is located in motif II. Of note, two oxygen atoms (O2‟ and 
O3‟) of the ribose ring of SAH also form hydrogen bond interactions with the 
side chain of Glu1168. The nitro group of 5b occupies a region similar to the 
carboxylate group of SAH making similar interactions with the binding 
pocket. Hydrogen bonds between the oxygen atoms of the nitro group of 5b 
and the backbone NH of Gly1150 (motif I), Leu1151, and Val1580 (motif X) 
were also predicted by Glide (Figure 5.1).
18 
Docking and binding mode studies for the new, longer 
2-
isoxazoline are 
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5.2. Docking and binding mode of NSC derivatives 
With the aim to identify novel DNMT1 small molecule inhibitors with 
chemical scaffolds different from the currently known inhibitors, we 
performed, in collaboration with Prof. Jose Medina-Franco (Torrey Pines 
Institute for Molecular Studies, Port St. Lucie, FL, USA), a multistep 
structure-based virtual screening of more than 260,000 compounds obtained 
from the NCI Open Database.
125
  
In order to focus the virtual screening on compounds that could be 
promising for further development, we selected a subset of lead-like 
compounds.
126
 This selection was made based on properties and functional 
groups using the FILTER program
127
 that reduced the initial NCI Database to 
a subset of 65,375 compounds.  
Since no crystallographic structure of the catalytic site of human DNMT1 
was available at the time of this study, we used an established homology 
model
86
 in all steps of the virtual screening. This model has been successfully 
used for previous virtual screening
128
 and modeling studies.  
After selecting lead-like compounds, we employed a fast docking protocol 
to further filter the NCI lead-like set.
83
 The prepared set was docked into the 
DNMT1 active site using the GLIDE Extra Precision (XP) docking module. 
A total of 6 consensus compounds with favorable docking scores were 
identified out and the chemical structures are shown in Table 5.1. The 
compounds selected from the virtual screening with DNMT1 were tested 







                                                                Chapter 5: Docking and binding mode 




















TABLE 5.1. Calculated docking scores of 6 hits tested experimentally. 
 
Taking advantage of the biological results previously reported, the binding 
mode of the most active compound was realized. As shown in Figure 5.2, the 
2-amino-pyrimidine of NSC140052 forms H-bond with Lys1462, and 
carboxylate forms strong H-bond with Ser 1229 and Gly1230. It demonstrates 





Chapter 5: Docking and binding mode                                                                         a 





Figure 5.2. Binding mode of NSC140052 predicted by Glide. Hydrogen bonds are displayed 
as yellow dashes. Selected amino acids residues within 4.5 Å of NSC140052 are shown. 
 
Docking and binding mode studies for the new, pyrrolo[3,4-d]-pyrimidines 
are ongoing to evaluate the potency of these compounds in inhibiting the 





























Being responsible of DNA methylation, DNA methyltransferases are 
recognized as valuable epigenetic targets for the development of anti-cancer 
therapies. Nucleoside inhibitors exert their effects by incorporation into DNA 
inducing substantial DNA demethylation and reactivation of hypermethylated 
genes. Yet, they also carry considerable concerns about toxicity. Because of 
these problems, the search and the development of non-nucleoside 
compounds, which can effectively inhibit DNA methylation without being 
incorporated into DNA, is being actively pursued. Being interested in the 
development of small-molecule modulators of epigenetic targets, we focused 
our attention on: 
- Procaine/procainamide as a lead structure for further modification: we 
prepared constrained analogues with an oxazoline ring, then replaced with the 
more stable 
2
-isoxazoline. On the basis of the experimental evidence of the 
enzymatic as well as competition assays, we proposed 5b as a lead compound 
for the synthesis of new, longer analogues as “bisubstrate” inhibitors. Indeed, 
further studies were performed to develop analogues endowed with improved 
enzyme binding properties and higher inhibitory potency (from 2 to 10 fold 
more active than the lead). 
- Compounds obtained from a docking-based virtual screening approach: 
starting from 260,000 molecules, six of them were synthesized and tested as 
DNMT1 inhibitors. Among them, NSC140052 became the starting point for 
the synthesis of new pyrrolo-pyrimidines. Docking studies as well as 
biological assays are ongoing to evaluate the potency of these new compounds 
in inhibiting the activity of DNMT1. However, preliminary data show that 
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All chemicals were purchased from Sigma Aldrich (Milan, Italy) or from Alfa 
Aesar GmbH (Karlsruhe, Germany) and were of the highest purity. All 
solvents were reagent grade and, when necessary, were purified and dried by 
standard methods. All reactions requiring anhydrous conditions were 
conducted under a positive atmosphere of nitrogen in oven-dried glassware. 
Standard syringe techniques were used for anhydrous addition of liquids. 
Reactions were routinely monitored by TLC performed on aluminum-backed 
silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) with spots 
visualized by UV light (λ = 254, 365 nm) or using a KMnO4 alkaline solution. 
Solvents were removed using a rotary evaporator operating at a reduced 
pressure of∼10 Torr. Organic solutions were dried over anhydrous Na2SO4. 
Chromatographic separations were performed on silica gel (silica gel 60, 
0.015-0.040 mm; Merck DC) columns. Melting points were determined on a 
Stuart SMP30 melting point apparatus in open capillary tubes and are 
uncorrected. 
1
H NMR spectra were recorded at 300MHz on a Bruker Avance 
300 spectrometer. Chemical shifts are reported in δ (ppm) relative to the 
internal reference tetramethylsilane (TMS). When compounds were tested as 
salts, NMR data refer to the free base. Mass spectra were recorded on a 
Finnigan LCQ DECA TermoQuest (San Jose, USA) mass spectrometer in 
electrospray positive and negative ionization modes (ESI-MS). Purity of tested 
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General procedure for the synthesis of oximes (7) 
To a suspension of the proper aldehyde (30.0 mmol) and hydroxylamine 
hydrochloride (2.29 g, 33.0 mmol) in a 1:1 mixture of H2O/MeOH (40 mL), an 
aqueous solution of Na2CO3 (1.59 g, 15.0 mmol, 20 mL) was slowly added. 
The resulting mixture was stirred at room temperature for 3h, and then 
methanol was evaporated. The aqueous phase was extracted with Et2O (3 x 30 
mL). The combined organic phases were washed with brine (30 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give the title compounds 7, 





Pale yellow oil, 96% yield. 
1
H NMR (300 MHz, CDCl3): δ 9.15 (br s, 1H), 







Yellow solid, 95% yield. 
1
H NMR (300 MHz, CDCl3): δ 8.25 (d, J = 8.7 Hz, 
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White solid, 94% yield. 
 1
H NMR (300 MHz, CDCl3): δ 8.10 (s, 1H), 8.05 (br 




7d: (4-[[(4-methylphenyl)sulfonyl]oxy]-benzaldehyde oxime 
 
White solid, 99% yield. 
1
H NMR (300 MHz, CDCl3): δ 8.08 (s, 1H), 7.71 (d, J 
= 8.4 Hz, 2H), 7.50 (d, J = 8.7 Hz, 2H), 7.43 (s, 1H), 7.31 (d, J = 8.4 Hz, 2H), 







Pale yellow solid, 91% yield. 55:45 mixture of geometric isomers a and b. 
1
H 
NMR (300 MHz, CDCl3): δ 8.41 (br s, 1H, isomer a), 7.88 (br s, 1H, isomer 
b), 7.57 (t, J = 6.3, 1H, isomer b), 7.45–7.15 (m, 5H, isomer a and 5H isomer 
b), 6.93 (t, J = 5.3 Hz, 1H, isomer a), 3.75 (d, J = 5.3 Hz, 2H, isomer a), 3.57 
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7i: (p-nitrophenyl)-acetaldehyde oxime 
 
Yellow solid, 87% yield. 60:40 mixture of geometric isomers a and b. 
1
H 
NMR (300 MHz, CDCl3): δ 8.19 (m, 2H, isomer a and 2H, isomer b) 7.92 (br 
s, 1H, isomer a), 7.55 (t, J = 6.1, 1H, isomer b), 7.48 (br s, 1H, isomer b), 
7.42–7.38 (m, 2H, isomer a and 2H, isomer b), 6.90 (t, J = 5.5 Hz, 1H, isomer 




7j: (p-methoxyphenyl)acetaldehyde oxime 
 
White solid, 90% yield. 55:45 mixture of geometric isomers a and b. 
1
H NMR 
(300 MHz, CDCl3): δ 7.65 (br s, 1H, isomer a), 7.51 (t, J = 6.2, 1H, isomer b), 
7.23 (br s, 1H, isomer b), 7.20–7.09 (m, 2H, isomer a and 2H, isomer b) 6.93–
6.78 (m, 3H, isomer a and 2H, isomer b), 3.82 (s, 3H, isomer a and 3H, isomer 




7l: 4-(tert-Butoxycarbonyl)benzaldehyde oxime 
 
4-(tert-Butoxycarbonyl)benzaldehyde was prepared according to a described 
procedure
134
 and the corresponding oxime 7l was prepared according to the 
general procedure reported above. White solid, 70% yield. 
1
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CDCl3): δ 9.23 (br s, 1H), 8.18 (s, 1H), 8.00 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 





General procedure for the synthesis of chlorooximes (10) 
To a solution of the proper aldoxime (2.75 mmol) in CHCl3 (10 mL), pyridine 
was added (20.0 μL, 0.27 mmol). The reaction mixture was heated at 40 °C, 
and N-chlorosuccinimide (0.40 g, 3.03 mmol) was added portionwise. After 
the reaction was complete (0.5-3h, monitored by TLC), the mixture was 
diluted with CH2Cl2 (30 mL) and washed with brine (3 x 10 mL). The organic 
phase was dried (Na2SO4), filtered, and concentrated in vacuo to give the title 





Pale yellow amorphous solid, 98% yield. 
1
H NMR (300 MHz, CDCl3): δ 8.62 





Pale yellow solid, 97% yield. 
1
H NMR (300 MHz, CDCl3): δ 8.31 (br s, 1H), 
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Yellow solid, 97% yield. 
1
H NMR (300 MHz, CDCl3): δ 7.78 (d, J = 8.4 Hz, 




White solid, 99% yield. 
1
H NMR (300 MHz, CDCl3): δ 7.97 (s, 1H), 7.78 (d, J 
= 8.4 Hz, 2H), 7.72 (d, J = 7.8 Hz, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.03 (d, J = 





Yellow solid, 95% yield. 
1
H NMR (300 MHz, CDCl3): δ 8.15 (br s, 1H), 7.45–




Pale yellow solid, 96% yield. 
1
H NMR (300 MHz, CDCl3): δ 8.21 (d, J = 8.4 
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Pale yellow solid, 96% yield. 
1
H NMR (300 MHz, CDCl3): δ 9.29 (br s, 1H), 
7.17 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 3.78 (s, 3H), 3.72 (s, 2H). 
10l: N-hydroxy-2-(4-tert-butoxycarbonylphenyl)acetimidoyl chloride 
 
White solid, 80% yield. 
1
H NMR (300 MHz, CDCl3): δ 8.10 (s, 1H), 8.05 (d, J 
= 8.8 Hz, 2H), 7.89 (d, J = 8.8 Hz, 2H), 1.60 (s, 9 H). 
General procedure for the synthesis of 3-substituted-5-hydroxymethyl- 
4,5-dihydroisoxazoles (8) 
To a vigorously stirred solution of the proper aldoxime (7.00 mmol) and 
allylic alcohol (0.81 mg, 0.95 mL, 14.0 mmol) in CH2Cl2 (50 mL) at 0 °C, a 
solution of common bleach (3% aqueous solution of NaOCl, 35 mL, 14.0 
mmol) was added dropwise, keeping the temperature below 5 °C. The 
resulting biphasic mixture was vigorously stirred at room temperature for 15 
min. The aqueous phase was separated and extracted with CH2Cl2 (3 x 20 mL). 
The combined organic phases were washed with brine (25 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo. The residue was purified by 
silica gel chromatography (EtOAc/hexane) to give the title compounds 8, 
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White solid, 87% yield; mp (EtOAc/hexane) 83–84 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 7.72–7.60 (m, 2H), 7.45–7.35 (m, 3H), 4.94–4.81 (m, 1H), 3.88 
(ddd, J = 12.1, 6.3, 3.3 Hz, 1H), 3.68 (ddd, J = 12.1, 6.3, 4.7 Hz, 1H), 3.39 (dd, 
J = 16.5, 10.4 Hz, 1H), 3.29 (dd, J = 16.5, 8.0 Hz, 1H), 2.09 (t, J = 6.3 Hz, 1H). 





Pale-yellow solid, 82%; mp (MeOH) 141–143 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 8.30 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 8.4 Hz, 2H), 5.02–4.92 (m, 
1H), 3.96 (ddd, J = 12.1, 4.4, 3.6 Hz, 1H), 3.72 (ddd, J = 12.1, 7.7, 4.4 Hz, 1H), 
3.42 (dd, J = 16.5, 10.5, 1H), 3.36 (dd, J = 16.5, 8.5 Hz, 1H), 1.92–1.84 (m, 





White solid, 83% yield; mp (EtOAc) 144–146 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 7.60 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 4.89–4.79 (m, 
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White solid, 83% yield; mp (i-PrOH) 85–87 °C. 
1
H NMR (300 MHz, CDCl3): 
δ 7.68 (d, J = 8.0 Hz, 2H), 7.56 (d, J = 8.0 Hz, 2H), 7.30 (d, J=8.0 Hz, 2H), 
7.00 (d, J = 8.0 Hz, 2H), 4.90–4.79 (m, 1H), 3.84 (dd, J = 12.4, 3.3 Hz, 1H), 
3.65 (dd, J = 12.4, 4.4 Hz, 1H), 3.32 (dd, J = 16.8, 11.0 Hz, 1H), 3.22 (dd, J = 





Pale-yellow oil, 80% yield. 
1
H NMR (300 MHz, CDCl3): δ 7.40–7.15 (m, 5H), 
4.70–4.58 (m, 1H), 3.71 (dd, J = 12.1, 3.3 Hz, 1H), 3.67 (s, 2H), 3.51 (dd, J = 
12.1, 5.0 Hz, 1H), 2.85 (dd, J = 17.1, 10.5 Hz, 1H), 2.71 (dd, J = 17.1, 7.7 Hz, 





Yellow solid, 93% yield; mp (EtOAc/hexane) 69–71 °C. 
1
H NMR (300 MHz, 
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3.89–3.70 (m, 3H), 3.53 (dd, J = 12.2, 4.1Hz, 1H), 2.89 (dd, J = 17.6, 10.7 Hz, 





White solid, 78% yield; mp (isopropyl ether) 70–71 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 7.11 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.5 Hz, 2H), 4.66–4.54 (m, 
1H), 3.76 (s, 3H), 3.66 (dd, J = 12.3, 3.2 Hz, 1H), 3.58 (s, 2H), 3.48 (dd, J = 
12.3, 4.6 Hz, 1H), 2.82 (dd, J = 17.3, 11.0 Hz, 1H), 2.68 (dd, J = 17.3, 7.8. Hz, 






White solid, 68% yield; mp (i-PrOH) 89–91 °C. 
1
H NMR(300 MHz, CDCl3): 
δ 7.99 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H), 4.96–4.84 (m, 1H), 3.90 
(dd, J = 12.4, 3.0 Hz, 1H), 3.70 (dd, J = 12.4, 4.1 Hz, 1H), 3.40 (dd, J = 16.8, 
10.7 Hz, 1H), 3.30 (dd, J = 16.8, 8.2 Hz, 1H), 2.20 (br s, 1H), 1.60 (s, 9H). 
ESI-MS m/z: 278 (M+H)
+
. 
General procedure for the synthesis of (3-substituted-4,5-dihydroisoxazol- 
5-yl)methyl methanesulfonates (9) 
To a solution of the proper (3-substituted-4,5-dihydroisoxazol-5-yl)methanol 8 
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methanesulfonyl chloride (0.16 mL, 2.00 mmol) was added at 0 °C. The 
resulting mixture was stirred at room temperature for 45 min, and then the 
solvent was evaporated. The residue was taken up with water (20 mL) and 
extracted with CH2Cl2 (3 x 20 mL). The combined organic phases were 
washed with 1N HCl (2 x 10 mL), NaHCO3, saturated aqueous solution (2 x 
10 mL), and brine (10 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo. Mesylates 9 were obtained in quantitative yields and used without 
further purification in the subsequent reaction. Recrystallization from the 
suitable solvent gave an analytical sample. 
9a: 5-hydroxymethyl-3-phenyl-4,5-dihydroisoxazole methanesulfonate 
 
White solid; mp (i-PrOH) 109–111 °C. 
1
H NMR (300 MHz, CDCl3): δ 7.70–
7.60 (m, 2H), 7.42–7.38 (m, 3H), 5.06–4.96 (m, 1H), 4.39 (dd, J = 11.3, 3.9Hz, 
1H), 4.27 (dd, J = 11.3, 5.0Hz, 1H), 3.45 (dd, J = 17.0, 11.0 Hz, 1H), 3.30 (dd, 






White solid; mp: (MeOH/H2O) 171–173 °C. 
1
H NMR (300 MHz, CDCl3): δ 
8.29 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 8.8 Hz, 2H), 5.19–5.06 (m, 1H), 4.45 (dd, 
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White solid; mp: (EtOAc) 146–148 °C. 
1
H NMR (300 MHz, CDCl3): δ 7.60 (d, 
J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 5.04–4.94 (m, 1H), 4.40 (dd, J = 11.3, 
4.1 Hz, 1H), 4.34 (dd, J = 11.3, 5.0 Hz, 1H), 3.85 (s, 3H), 3.48 (dd, J = 16.8, 







White solid; mp: (i-PrOH) 123–125 °C. 
1
H NMR (300 MHz, CDCl3): δ 7.69 
(d, J = 8.5 Hz, 2H), 7.57 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 7.02 (d, 
J = 8.5 Hz, 2H), 5.07–4.95 (m, 1H), 4.38 (dd, J = 11.6, 3.9Hz, 1H), 4.31 (dd, J 
= 11.6, 3.9Hz, 1H), 3.44 (dd, J = 17.1, 11.0 Hz, 1H), 3.24 (dd, J = 17.1, 7.1 Hz, 
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9h: 3-benzyl-5-hydroxymethyl-4,5-dihydroisoxazole methanesulfonate 
 
White solid; mp (i-PrOH): 43–44 °C. 
1
H NMR (300 MHz, CDCl3): δ 7.38–
7.20 (m, 5H), 4.82–4.72 (m, 1H), 4.22 (dd, J = 11.3, 3.9 Hz, 1H), 4.15 (dd, J = 
11.3, 5.0 Hz, 1H), 3.66 (s, 2H), 2.98 (s, 3H), 2.96 (dd, J = 17.6, 10.9 Hz, 1H), 






Pale-yellow solid; mp (i-PrOH): 107–109 °C. 
1
H NMR (300 MHz, CDCl3): δ 
8.24 (d, J = 8.8 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 4.92–4.81 (m, 1H), 4.29 (dd, 
J = 11.3, 3.8 Hz, 1H), 4.21 (dd, J = 11.3, 4.4 Hz, 1H), 3.83 (s, 2H), 3.08 (s, 







White solid; mp (i-PrOH): 104–105 °C. 
1
H NMR (300 MHz, CDCl3): δ 7.12 
(d, J = 8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 4.83–4.72 (m, 1H), 4.24 (dd, J = 
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3.03 (s, 3H), 2.96 (dd, J = 17.3, 11.0 Hz, 1H), 2.72 (dd, J = 17.3, 7.1 Hz, 1H). 






White solid; mp (i-PrOH): 128–129 °C. 
1
H NMR (300 MHz, CDCl3): δ 8.02 
(d, J = 8.8 Hz, 2H), 7.68 (d, J = 8.8 Hz, 2H), 5.12–4.99 (m, 1H), 4.42 (dd, J = 
11.7, 4.1 Hz, 1H), 4.35 (dd, J = 11.7, 5.0 Hz, 1H), 3.52 (dd, J = 17.0, 11.1 Hz, 




General procedure for the synthesis of 3-substituted-5-(N,N-
dimethylaminomethyl)-4,5-dihydroisoxazoles (5) 
The proper mesylate (1.30 mmol) was dissolved in a 2 M THF solution of 
dimethylamine (20 mL, 39.0 mmol) under N2 atmosphere. The vessel was 
sealed, and the reaction was stirred at 100 °C for 12h and then concentrated in 
vacuo. The residue was purified by silica gel chromatography (EtOAc/hexane) 
to give the title compounds. Compounds 5c,d and 5l were recrystallized from 
the appropriate solvent. Compounds 5a,b, and 5h-j were dissolved in 4N HCl 
in dioxane, and the mixture was stirred at room temperature for 10 min. The 
solvent was concentrated in vacuo, and the resulting solid was recrystallized 
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White solid, 79% yield; mp (i-PrOH) 188–190 °C; free base. 
1
H NMR (300 
MHz, CDCl3): δ 7.62–7.51 (m, 2H), 7.35–7.23 (m, 3H), 4.86–4.72 (m, 1H), 
3.30 (dd, J = 16.5, 10.5 Hz, 1H), 3.05 (dd, J = 16.5, 8.0Hz, 1H), 2.53 (dd, J = 







White solid, 78% yield; mp (MeOH) 262 °C (decomp); free base. 
1
H NMR 
(300 MHz, CDCl3): δ 8.26 (d, J = 8.7 Hz, 2H), 7.84 (d, J = 8.7 Hz, 2H), 5.06–
4.90 (m, 1H), 3.43 (dd, J = 16.7, 10.6 Hz, 1H), 3.24 (dd, J = 16.7, 8.1 Hz, 1H), 
2.66 (dd, J = 12.8, 6.4 Hz, 1H), 2.55 (dd, J = 12.8, 6.0 Hz, 1H), 2.34 (s, 6H). 
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White solid, 75% yield; mp (isopropyl ether) 75–76 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 7.61 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 4.93–4.80 (m, 
1H), 3.83 (s, 3H), 3.40 (dd, J = 16.7, 10.5 Hz, 1H), 3.14 (dd, J = 16.7, 7.6 Hz, 
1H), 2.63 (dd, J = 12.9, 6.7 Hz, 1H), 2.55 (dd, J = 12.9, 5.6 Hz, 1H), 2.35 (s, 






White solid, 78% yield; mp (i-PrOH) 123–124 °C. 
1
H NMR (300 
MHz,CDCl3): δ 7.70 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 
8.2 Hz, 2H), 7.00 (d, J = 8.2 Hz, 2H), 4.93–4.82 (m, 1H), 3.32 (dd, J = 16.8, 
10.5 Hz, 1H), 3.12 (dd, J = 16.8, 8.0 Hz, 1H), 2.60 (dd, J = 12.9, 6.3 Hz, 1H), 







White solid, 76% yield; mp (EtOAc) 80–82 °C; free base. 
1
H NMR (300 MHz, 
CDCl3): δ 7.35–7.22 (m, 5H), 4.70–4.60 (m, 1H), 3.68 (s, 2H), 2.86 (dd, J = 
17.0, 10.4 Hz, 1H), 2.60 (dd, J = 17.0, 8.0Hz, 1H), 2.50 (dd, J = 12.8, 6.5 Hz, 
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White solid, 79% yield; mp (EtOH/Et2O) 164–167 °C; free base. 
1
H NMR 
(300 MHz, CDCl3): δ 8.20 (d, J = 8.8 Hz, 2H), 7.42 (d, J = 8.8 Hz, 2H), 4.78–
4.66 (m, 1H), 3.78 (s, 2H), 2.89 (dd, J = 17.0, 10.4 Hz, 1H), 2.65 (dd, J = 17.0, 
8.0 Hz, 1H), 2.52 (dd, J = 12.9, 6.5 Hz, 1H), 2.40 (dd, J = 12.9, 5.5 Hz, 1H), 






White solid, 79% yield; mp (acetone/Et2O) 126–128 °C; free base. 
1
H NMR 
(300 MHz, CDCl3): δ 7.14 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 4.69–
4.59 (m, 1H), 3.79 (s, 3H), 3.61 (s, 2H), 2.86 (dd, J = 16.9, 10.3 Hz, 1H), 2.59 
(dd, J = 16.9, 8.0 Hz, 1H), 2.49 (dd, J = 12.8, 6.6 Hz, 1H), 2.33 (dd, J = 12.8, 
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White solid, 81% yield; mp (i-PrOH) 75–76 °C. 
1
H NMR (300 MHz, CDCl3): 
δ 8.00 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 4.98–4.84 (m, 1H), 3.41 
(dd, J = 16.7, 10.6Hz, 1H), 3.18 (dd, J = 16.7, 8.2Hz, 1H), 2.63 (dd, J = 12.9, 





dihydroisoxazole hydrochloride (5g) 
 
To a solution of 5d (0.11 g, 0.29 mmol) in EtOH (5 mL) an aqueous solution 
of 1N NaOH (1.45 mL, 1.45 mmol) was added. The mixture was heated at 
reflux and stirred for 1h. The reaction mixture was then cooled to room 
temperature, treated with HCl 1N to pH 9, and concentrated in vacuo. The 
residue was treated with water (30 mL) and extracted with EtOAc (3 x 30 
mL). The combined organic phases were washed with brine (10 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give the title compound as a 
free base (61.2 mg, 96%), which was converted in the corresponding 
hydrochloride salt following the general procedure described for compounds 
5a,b, and 5h-j; mp 232–235 °C (decomp); free base. 
1
H NMR (300 
MHz,DMSO-d6): δ 9.90 (br s, 1H), 7.47 (d, J = 8.5 Hz, 2H), 6.80 (d, J = 8.5 
Hz, 2H), 4.77–4.66 (m, 1H), 3.37 (dd, J = 16.9, 11.7 Hz, 1H), 3.07 (dd, J = 
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A mixture of TFA and DCM (1:3, 12 mL) was added to compound 5l (0.31 g, 
1.03 mmol). The reaction was stirred at room temperature overnight and then 
concentrated in vacuo to give the title compound as a white solid (0.26 g, 
99%), which was recrystallized from MeOH/H2O. White solid; mp 249–
251 °C (decomp). 
1
H NMR (300 MHz, DMSO-d6): δ 9.96 (br s, 1H), 8.0 (d, J 
= 8.2 Hz, 2H), 7.78 (d, J = 8.2 Hz, 2H), 5.25–5.15 (m, 1H), 3.80–3.63 (m, 1H), 




dihydroisoxazole hydrochloride (5f). 
 
To an ice cooled solution of 5b free base (0.16 g, 0.64 mmol) in AcOH (36 
mL) zinc powder (0.340g, 5.13 mmol) was added. The resulting mixture was 
stirred at room temperature for 1h, the solid was filtered off, and the solvent 
was evaporated. The residue was taken up with EtOAc (20 mL) and washed 
with NaHCO3 saturated aqueous solution twice. The organic phase was dried 
(Na2SO4), filtered, and concentrated in vacuo. The residue was purified by 
silica gel chromatography (CH2Cl2/MeOH) to give the title compound (0.12 g, 
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the general procedure described for compounds 5a,b, and 7h-j. White solid; 
mp 268–270 °C (decomp); free base. 
1
H NMR (300 MHz, CDCl3): δ 7.47 (d, J 
= 8.8 Hz, 2H), 6.67 (d, J = 8.8 Hz, 2H), 4.86–4.76 (m, 1H), 3.87 (br s, 2H); 
3.36 (dd, J = 16.5, 10.3 Hz, 1H), 3.11 (dd, J = 16.5, 7.8 Hz, 1H), 2.60 (dd, J = 





dihydroisoxazole hydrochloride (5k). 
 
Reduction of compound 5i (0.15 g, 0.58 mmol) according to the procedure 
used for 5f yielded the free amine (0.10 g, 75%), which was converted to the 
hydrochloride salt following the general procedure described for compounds 
5a,b, and 5h-j. White solid; mp (EtOH/Et2O) 211–212 °C (decomp); free base. 
1
H NMR (300 MHz, CDCl3): δ 6.99 (d, J = 8.2 Hz, 2H), 6.62 (d, J = 8.2 Hz, 
2H), 4.79–4.46 (m, 1H), 3.75 (br s, 2H), 3.54 (s, 2H), 2.86 (dd, J = 17.0, 10.3 
Hz, 1H), 2.58 (dd, J = 17.0, 10.3 Hz, 1H), 2.50 (dd, J = 12.8, 7.0 Hz, 1H), 2.35 
(dd, J = 12.8, 5.5 Hz, 1H), 2.26 (s, 6H). ESI-MS m/z: 234 (M+H)
+
.  
General procedures for the synthesis of tert-Butyl 3-substituted-6,6a-
dihydro-3aH-pyrrolo[3,4-d]isoxazole-5(4H)-carboxylates (12a-d, 12h-j, 
12l). 
Conventional conditions. To a solution of N-Boc-Δ
3
-pyrroline 11 (0.17 g, 1.00 
mmol) in EtOAc (5 mL) were added solid NaHCO3 (0.42 g, 5.00 mmol) and 
the proper chloroxime 10 (4 equiv added portionwise: 1 equiv the first day, 0.5 
equiv/day for the next six days). The mixture was vigorously stirred at room 
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organic layer was separated. The aqueous layer was further extracted with 
EtOAc, and the combined organic phase was dried over anhydrous sodium 
sulfate. The solvent was evaporated, and the crude material was purified by 
silica gel chromatography (cyclohexane/EtOAc 7:3) to give the corresponding 
cycloadduct. 
Microwave batch conditions. The proper chloroxime 10 (1.00 mmol) was 
dissolved in EtOAc (5 mL) at room temperature in a 10 mL CEM pressure 
vessel equipped with a stirrer bar. N-Boc-Δ
3
-pyrroline 11 (0.17 g, 1.00 mmol), 
solid NaHCO3 (0.34 g, 4.00 mmol), and H2O (50 μL) were added, and the vial 
was sealed and heated in a CEM Discover microwave synthesizer to 80 °C 
(measured by the vertically focused IR temperature sensor) for 30 min. The 
reaction cycle was repeated another two times, each time adding additional 0.5 
equiv of chloroxime 10 (2 equiv total). The solid was filtered off, and the 
solution was dried over anhydrous sodium sulfate. The solvent was evaporated, 
and the crude material was purified by silica gel column chromatography 
(cyclohexane/EtOAc 7:3) to give the corresponding cycloadduct. 
Continuous flow conditions. A 0.25M solution of N-Boc-
3
-pyrroline 11 (0.17 
g, 1.00 mmol) in EtOAc (4 mL) and a 0.37M solution of the proper 
chloroxime 10 (1.50 mmol) in EtOAc (4 mL) were prepared. The two reactant 
streams were mixed using a simple T-piece and delivered to an Omnifit glass 
column (6.6 mm id by 100 mm length) filled with K2CO3 (0.54 g, 4.00 mmol) 
heated at 90 °C at a total flow rate of 0.1 mL min
-1
, equivalent to a residence 
time of about 10 min. A 100 psi backpressure regulator was applied to the 
system. The solvent was evaporated, and the product was purified by silica gel 
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White solid, 69% yield; mp (EtOAc/hexane) 146–147 °C (decomp). 
1
H NMR 
(300 MHz, CDCl3): δ 7.65–7.55 (m, 2H), 7.45–7.35 (m, 3H), 5.28 (ddd, J = 
9.3, 5.5, 1.1 Hz, 1H), 4.25–4.15 (m, 1H), 3.90 (d, J = 12.6 Hz, 1H), 3.51–3.70 





12b:  tert-Butyl 3-(4-nitrophenyl)-6,6a-dihydro-3aH-pyrrolo[3,4-
d]isoxazole-5(4H)-carboxylate 
 
Pale-yellow solid, 60% yield; mp (EtOAc/hexane) 189–190 °C (decomp). 
1
H 
NMR(300 MHz,CDCl3):δ 8.28 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 
5.40 (dd, J = 8.3, 4.1 Hz, 1H), 4.30–4.20 (m, 1H), 4.03 (d, J = 13.2 Hz, 1H), 





12c:  tert-Butyl 3-(4-methoxyphenyl)-6,6a-dihydro-3aH-pyrrolo[3,4-
d]isoxazole-5(4H)-carboxylate 
 
White solid, 73% yield; mp (EtOAc/hexane) 137–138 °C. 
1
H NMR (300 MHz, 
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5.2Hz, 1H), 4.25–4.15 (m, 1H), 3.95 (d, J = 12.6 Hz, 1H), 3.83 (s, 3H), 3.72–








Pale-yellow solid, 58% yield; mp (EtOAc/hexane) 189–190 °C. 
1
H NMR (300 
MHz, CDCl3): δ 7.72 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 
7.8 Hz, 2H), 7.04 (d, J = 7.8 Hz, 2H), 5.34 (dd, J = 9.5, 5.1 Hz, 1H), 4.25– 
4.13 (m, 1H), 4.00 (d, J = 12.9 Hz, 1H), 3.85–3.55 (m, 3H), 2.46 (s, 3H), 1.42 





12h:  tert-Butyl 3-benzyl-6,6a-dihydro-3aH-pyrrolo[3,4-d]isoxazole-
5(4H)-carboxylate 
 
Pale-yellow oil, 71% yield. 
1
H NMR (300 MHz, CDCl3): δ 7.21–7.37 (m, 5H), 
5.08 (ddd, J = 9.1, 5.6, 1.5 Hz, 1H), 3.95–3.80 (m, 3H), 3.62–3.50 (m, 2H), 
3.45 (dd, J = 13.5, 5.6 Hz, 1H), 3.29 (dd, J = 11.7, 8.5Hz, 1H), 1.45 (s, 9H). 
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12i:  tert-Butyl 3-(4-nitrobenzyl)-6,6a-dihydro-3aH-pyrrolo[3,4-
d]isoxazole-5(4H)-carboxylate 
 
Yellow solid, 67% yield; mp (EtOAc/hexane) 108–110 °C. 
1
H NMR (300 
MHz, CDCl3): δ 8.20 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 8.5Hz, 2H), 5.12 (dd, J = 
8.2, 4.8 Hz, 1H), 4.00–3.80 (m, 2H), 3.75–3.55 (m, 3H), 3.45 (dd, J = 12.6, 4.8 






12j:  tert-Butyl 3-(4-methoxybenzyl)-6,6a-dihydro-3aH-pyrrolo[3,4-
d]isoxazole-5(4H)-carboxylate 
 
Pale-yellow oil, 64% yield. 
1
H NMR (300 MHz, CDCl3): δ 7.15 (d, J = 8.5Hz, 
2H), 6.88 (d, J = 8.5 Hz, 2H), 5.07 (ddd, J = 9.1, 5.8, 1.6 Hz, 1H), 3.80 (s, 3H), 
3.85–3.75 (m, 2H), 3.60–3.40 (m, 4H), 3.30 (dd, J = 11.8, 8.5Hz, 1H), 1.45 (s, 
9H). ESI-MS m/z: 355 (M+Na)
+
. 
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White solid, 69% yield; mp (EtOAc/hexane) 143–145 °C. 
1
H NMR(300 MHz, 
CDCl3): δ 8.02 (d, J = 8.2 Hz, 2H), 7.67 (d, J = 8.2 Hz, 2H), 5.34 (dd, J = 9.4, 
5.6 Hz, 1H), 4.27–4.18 (m, 1 H), 4.00 (d, J = 12.9 Hz, 1H), 3.80–3.58 (m, 3H), 
1.65 (s, 9H), 1.40 (s, 9H). ESI-MS m/z: 389 (M+H)
+
. 
General procedure for the synthesis of 5-methyl-3-substituted-4,5,6,6a-
tetrahydro-3aH-pyrrolo[3,4-d]isoxazoles (6). 
A solution of the proper N-Boc protected derivative 12 (1.00 mmol) in 4 M 
HCl solution in dioxane (5.0 mL, 20.0 mmol) was stirred for 1 h and then 
concentrated in vacuo. The residue was treated with water (10 mL) and 
washed with CH2Cl2 twice. The aqueous phase was basified with NaHCO3 and 
extracted with EtOAc (3 x 30 mL). The combined organic phases were washed 
with brine (10 mL), dried (Na2SO4), filtered, and concentrated in vacuo to 
afford the crude, unprotected derivative, which was used for the next step 
without further purification. 
To a solution of the proper unprotected 4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-
d]isoxazole (0.80 mmol) in acetone (8 mL), K2CO3 (0.44 g, 3.20 mmol) and 
methyl iodide (49 µL, 0.80 mmol) were added. The resulting mixture was 
stirred at room temperature for 12h, the solid was filtered off, and the solvent 
was evaporated. The residue was purified by silica gel chromatography 
(CH2Cl2/MeOH) to give the title compounds. Derivatives 6a-d were 
recrystallized from the appropriate solvent. Compounds 6h and 6i were 
converted in the corresponding hydrochloride salts following the general 
procedure described for compounds 5a,b and 5h-j. Compound 6j (53.0 mg, 
0.21 mmol) was dissolved in EtOH (3 mL), and a solution of oxalic acid (30.0 
mg, 0.24 mmol) in EtOH (1 mL) was added. The mixture was stirred at room 
temperature for 10 min, and the resulting solid was recrystallized from 





Chapter 7:Experimental section                                                                                   a 
- 122 - 
 
6a: 5-methyl-3-phenyl-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole  
 
White solid, 48% yield; mp (EtOAc/hexane) 119–121 °C (decomp). 
1
H NMR 
(300 MHz, CDCl3): δ 7.50–7.68 (m, 2H), 7.28–7.40 (m, 3H), 5.22 (dd, J = 9.1, 
4.5 Hz, 1H), 4.21–4.16 (ddd, J = 9.1, 7.4, 1.7 Hz, 1H), 3.26 (d, J = 11.0 Hz, 
1H), 3.09 (d, J = 9.6 Hz, 1H), 2.51 (dd, J = 9.6, 7.4 Hz, 1H), 2.45 (dd, J = 11.0, 






White solid, 38% yield; mp (EtOAc/hexane) 161–162 °C. 1H NMR (300 MHz, 
CDCl3): δ 8.27 (d, J = 7.7 Hz, 2H), 7.85 (d, J = 7.7Hz, 2H), 5.33 (dd, J = 4.3, 
9.5, 1H), 4.23–4.17 (m, 1H), 3.33 (d, J = 11.2 Hz, 1H), 3.08 (d, J = 9.7, 1H), 






White solid, 33% yield; mp (EtOAc/hexane) 158–160 °C. 
1
H NMR (300 MHz, 
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4.6 Hz, 1H), 4.17–4.12 (m, 1H), 3.84 (s, 3H), 3.25 (d, J = 10.9 Hz, 1H), 3.07 






White solid, 32% yield; mp (EtOAc/hexane) 122–123 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 7.70 (d, J = 8.5 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 
Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 5.22 (dd, J = 9.4, 4.1 Hz, 1H), 4.14–4.08 (m, 
1H), 3.28 (d, J = 11.9 Hz, 1H), 3.07 (d, J = 9.4, 1H), 2.49–2.38 (m, 5H), 2.33 






White solid, 31% yield; mp (EtOH/Et2O) 122–123 °C; free base. 
1
H NMR 
(300 MHz, CDCl3): δ 7.37–7.16 (m, 5H), 4.97 (dd, J = 4.6, 9.3 Hz, 1H), 3.89 
(d, J = 15.1 Hz, 1H), 3.50 (d, J = 15.1 Hz, 1H), 3.55–3.42 (m, 1H), 3.20 (d, J = 
10.9 Hz, 1H), 2.96 (d, J = 9.4 Hz, 1H), 2.31 (s, 3H), 2.26 (dd, J = 10.9, 4.6 Hz, 
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Pale-yellow solid, 40% yield; mp (EtOH/Et2O) 239–240 °C (decomp); free 
base. 
1
H NMR (300 MHz, CDCl3): δ 8.20 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 8.5 
Hz, 2H), 5.03 (dd, J = 9.3, 4.6 Hz, 1H), 3.93 (d, J = 15.5 Hz, 1H), 3.64 (d, J = 
15.5Hz, 1H), 3.55–3.45 (m, 1H), 3.23 (d, J = 10.9Hz, 1H), 2.94 (d, J = 9.7Hz, 
1H), 2.31 (s, 3H), 2.27 (dd, J = 10.9, 4.6 Hz, 1H), 2.20 (dd, J = 9.7, 7.2 Hz, 






White solid, 34% yield; mp (Et2O/EtOH) 138–140 °C; free base. 
1
H NMR 
(300 MHz, CDCl3): δ 7.14 (d, J = 8.4Hz, 2H), 6.83 (d, J = 8.4 Hz, 2H), 4.94 
(dd, J = 9.2, 4.6Hz, 1H), 3.86–3.75 (m, 1H), 3.77 (s, 3H), 3.53–3.39 (m, 2H), 
3.17 (d, J = 10.9 Hz, 1H), 2.93 (d, J = 9.4 Hz, 1H), 2.29 (s, 3H), 2.23 (dd, J = 
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Colorless oil, 45% yield. 
1
H NMR (300 MHz, CDCl3): δ 8.00 (d, J = 8.8 Hz, 
2H), 7.70 (d, J = 8.8 Hz, 2H), 5.25 (dd, J = 9.6, 4.4 Hz, 1H), 4.22–4.15 (m, 
1H), 3.28 (d, J = 11.0 Hz, 1H), 3.06 (d, J = 9.3 Hz, 1H), 2.51 (dd, J = 9.3, 7.4 







Deprotection of compound 6d (70.0 mg, 0.19 mmol) according to the 
procedure used for 5g yielded the title compound as a white solid (40.5 mg, 
95%), which was recrystallized from EtOAc/hexane; mp 126–127 °C. 
1
H 
NMR (300 MHz, DMSO-d6): δ 9.87 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 6.79 (d, 
J = 8.5Hz, 2H), 5.05 (dd, J = 9.4, 4.3 Hz, 1H), 4.25–4.20 (m, 1H), 3.01 (d, J = 
10.8Hz, 1H), 2.85 (d, J = 9.5 Hz, 1H), 2.33 (dd, J = 9.5, 7.4 Hz, 1H), 2.25 (dd, 
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Reduction of compound 6b (0.14 g, 0.55 mmol) according to the procedure 
used for 5l yielded the free amine (0.10 g, 85%), which was converted to the 
hydrochloride salt following the general procedure described for compounds 
5a,b, and 5h-j. White solid; mp (EtOH/Et2O) 211–212 °C (decomp); free base. 
1
H NMR (300 MHz, CDCl3): δ 7.47 (d, J = 8.5 Hz, 2H), 6.67 (d, J = 8.5 Hz, 
2H), 5.15 (dd, J = 9.3, 4.4 Hz, 1H), 4.15–4.08 (m, 1H), 3.87 (br s, 2H), 3.22 (d, 
J = 10.7 Hz, 1H), 3.06 (d, J = 9.6 Hz, 1H), 2.55–2.40 (m, 2H), 2.32 (s, 3H). 






Reduction of compound 6i (0.14 g, 0.54 mmol) according to the procedure 
used for 5f yielded the free amine (0.10 g, 83%), which was converted to the 
oxalate salt following the general procedure described for compound 6j. White 
solid; mp (EtOH/Et2O) 164–165 °C; free base. 
1
H NMR (300 MHz, CDCl3): δ 
7.02 (d, J = 8.5 Hz, 2H), 6.64 (d, J = 8.5 Hz, 2H), 4.96 (dd, J = 9.3, 4.6Hz, 1H), 
3.77 (d, J = 15.1 Hz, 1H), 3.64 (br s, 2H), 3.49 (dd, 9.3, 7.5 Hz, 1H), 3.38 (d, J 
= 15.1 Hz, 1H), 3.19 (d, J = 10.9 Hz, 1H), 2.94 (d, J = 9.7 Hz, 1H), 2.31 (s, 
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Deprotection of compound 6i (0.20 g, 0.66 mmol) according to the procedure 
used for 5e yielded the title compounds (0.16 g, 99%).White solid; mp 
(methanol/H2O) 255–257 °C (decomp). 
1
H NMR (300 MHz, DMSO-d6): δ 
10.20 (br s, 1H), 8.02 (d, J = 8.5 Hz, 2 H), 7.84 (d, J = 8.5 Hz, 2H), 5.50 (dd, J 
= 9.6, 4.4 Hz, 1H), 4.82–4.70 (m, 1H), 3.98–3.80 (m, 1H), 3.78–3.60 (m, 1H), 
3.58–3.25 (m, 2H), 2.78 (s, 3H). ESI-MS m/z: 247 (M+H)
+
. 
General procedure for the synthesis of 5-(azidomethyl)-3-(4-
substitutedphenyl)-4,5-dihydroisoxazoles (14) 
To a solution of methanesulfonates 9 (6.67 mmol) in dry DMF (13 mL) 
sodium azide (1.30 g, 19.9 mmol) was added. The reaction mixture was stirred 
at 80 °C for 3h and then water (20 mL) was added. The aqueous layer was 
extracted with EtOAc (3 × 20 mL). The combined organic phases were 
washed with NaHCO3 saturated aqueous (20 mL) and brine (20 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give the desired which was 
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Yellow solid, 90% yield; mp 109–111 °C. 
1
H NMR (300 MHz, CDCl3):  8.28 
(d, J = 8.8 Hz, 2H), 7.85 (d, J = 8.8 Hz, 2H), 5.04–5.00 (m, 1H), 3.63 (dd, J = 




14b: tert-butyl 4-(5-(azidomethyl)-4,5-dihydroisoxazol-3-yl)benzoate 
 
Yellow solid, 92% yield; mp 82–84 °C. 
1
H NMR (300 MHz, CDCl3):  8.02 
(d, J =8.1 Hz, 2H), 7.71 (d, J = 8.1 Hz, 2H), 5.03–4.84 (m, 1H), 3.57 (dd, J = 
12.9, 4.4 Hz, 1H), 3.52–3.39 (m, 2H), 3.24 (dd, J = 16.7, 7.2 Hz, 1H), 1.60 (s, 
9H). ESI-MS m/z: 303 (M+H)
+
. 
General procedure for the synthesis of 5-(aminomethyl)-3-(4-
substitutedphenyl)-4,5-dihydroisoxazoles (15) 
To a solution of azides 14 (8.09 mmol) and water (2 mL) in MeOH (160 mL), 
triphenylphosphine (3.18 g, 12.1 mmol) was added. The reaction mixture was 
stirred at room temperature for 12h and then methanol was evaporated. The 
mixture was diluted with 1N HCl (30 mL), and washed with hexane (3 × 20 
mL). The aqueous phase was basified with NaHCO3 and extracted with EtOAc 
(3 × 30 mL). The combined organic phases were washed with brine (10 mL), 
dried (Na2SO4), filtered, and concentrated in vacuo to give the corresponding  
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Yellow solid, 73% yield; mp 156–158 °C. 
1
H NMR (300 MHz, CDCl3):  8.26 
(d, J = 8.8 Hz, 2H), 7.84 (d, J = 8.8 Hz, 2H), 4.95–4.87 (m, 1H), 3.40 (dd, J = 
16.6, 10.7 Hz, 1H), 3.23 (dd, J = 16.6, 7.9 Hz, 1H), 3.07 (dd, J = 13.4, 3.6 Hz, 
1H), 2.91 (dd, J = 13.4, 5.7 Hz, 1H), 1.40 (br s, 2H). ESI-MS m/z: 222 (M+H)
+
. 
15b: tert-butyl 4-(5-(aminomethyl)-4,5-dihydroisoxazol-3-yl)benzoate 
 
Yellow solid, 82% yield; mp 110–112 °C. 
1
H NMR (300 MHz, CDCl3):   
7.98 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H), 5.07–5.01 (m, 1H), 4.78 (br 
s, 2H), 3.40 (dd, J = 16.6, 10.7 Hz, 1H), 3.23 (dd, J = 16.6, 7.9 Hz, 1H), 3.00–
2.88 (m, 2H), 1.59 (s, 9H). ESI-MS m/z: 277 (M+H)
 +
. 
Synthesis of 4-chloropyrimidines 22 and 24 
22: 4-chloro-2,6-dimethylpyridine 
 
Triphenylphosfine (0.84 g, 1.60 mmol) and NCS (0.21 g, 1.60 mmol) were 
dissolved in dry 1,4-dioxane (5 mL) at room temperature in a 10 mL CEM 
pressure vessel equipped with a stirrer bar. After 30 minutes, 4-hydroxy-2,6-
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and heated in a CEM Discover microwave synthesizer to 105 °C (measured by 
the vertically focused IR temperature sensor) for 15 min. The mixture was 
basified with triethylamine (1 mL) and the solvent was evaporated. The crude 
material was purified by silica gel column chromatography (hexane/EtOAc 
7:3) to give the desired product. Pale-yellow oil, 87% yield. 
1
H NMR (300 
MHz, CDCl3): δ 7.04 (s, 1H); 2.69 (s, 3H); 2.48 (s, 3H). ESI-MS m/z: 143 
(M+H)
+
; 145 (30%) (M+2H)
+
. 
 24: N,N'-(4-chloropyrimidine-2,6-diyl)diacetamide 
 
A suspension of 2,6-diamino-4-chloropyrimidine (1.00 g, 6.92 mmol) in acetic 
anydride (5 mL) was refluxed for 3h. The solvent was removed and 10 mL of 
methanol were added. The yellow suspension was stirred at room temperature 
for 1h. The solvent was removed under reduced pressure, then 10 mL of water 
were added. The mixture was basified with 5% Na2CO3 to pH 8. The solid was 
filtered and washed with cold water. Yellow solid, 90% yield; mp 244–246 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 10.95 (s, 1H); 10.63 (s, 1H); 7.74 (s, 1H); 
2.19 (s, 3H); 2.15 (s, 3H). ESI-MS m/z: 229 (M+H)
+
; 231 (30%) (M+2H)
+
. 
General procedure for the synthesis of pyrimidin-amino benzoic acids 
(25-27) 
The proper 6-chloropyrimidine (0.88 mmol) and p-aminobenzoic acid (0.14 g, 
1.06 mmol) were dissolved in 2-propanol (1 mL) at room temperature in a 10 
mL CEM pressure vessel equipped with a stirrer bar. The vial was sealed and 
heated in a CEM Discover microwave synthesizer to 120 °C (measured by the 
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filtered off, and washed with 2-propanol and acetone to give the corresponding 
product. 
25: 4-((2,6-dimethylpyrimidin-4-yl)amino)benzoic acid 
 
White solid, 99% yield; mp 348–350 °C (decomp.); 
1
H NMR (300 MHz, 
DMSO-d6): δ 11.52 (br s, 1H); 8.00– 7.95 (m, 2H); 7.90–7.79 (m, 2H); 6.92(s, 
1H); 3.74 (s, 1H); 2.59 (s, 3H); 2.44 (s, 3H). ESI-MS m/z: 244 (M+H)
+
. 
26: 4-((2-amino-6-methylpyrimidin-4-yl)amino)benzoic acid 
 
White solid, 99% yield; mp 340–342 °C (decomp.); 
1
H NMR (300 MHz, 
DMSO-d6): δ 12.89 (m, 2H); 10.92 (s, 1H); 8.25–7.75 (m, 4H); 6.27 (s, 1H); 
2.30 (s, 3H). ESI-MS m/z: 245 (M+H)
+
. 
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For the synthesis of 27, the vial was heated to 120 °C for 1.5h. Pale-yellow 
solid, 99% yield; mp 345–347 °C (decomp.); 
1
H NMR (300 MHz, DMSO-d6): 
δ 11.87 (s, 1H); 11.61 (s, 1H); 11.06 (s, 1H); 8.10–7.74 (m, 4H); 6.86 (s, 1H); 
2.27 (s, 3H); 2.20 (s, 3H). ESI-MS m/z: 230 (M+H)
+
. 
General procedure for the synthesis of 4-((2,6-substitutedpyrimidin-4-
yl)amino)-N-((3-(4-substitutedphenyl-4,5-dihydroisoxazol-5-
yl)methyl)benzamides (16-19) 
To a solution of amines 15 (0.27 mmol) in dry 1:2 DMF/THF (1.5 mL), a 
mixture of 4-(2,6-substitutedpyrimidin-4-ylamino)benzoic acids 25-27 (0.27 
mmol), HOBt (10 mg, 0.65 mmol), HBTU (10 mg, 0.65 mmol), and DIPEA 
(N,N-Diisopropylethylamine) (0.23 mL, 1.29 mmol), in dry 1:3 DMF/THF 
(6.0 mL) was added dropwise at room temperature. The reaction mixture was 
stirred for 12h at room temperature and the solvents were then removed under 
vacuum. The residue was taken up with EtOAc (20 mL) and washed with 
NaHCO3 saturated aqueous solution (2 × 20 mL) and brine (20 mL). The 
organic phase was dried (Na2SO4), filtered, and concentrated in vacuo. The 





White solid, 80% yield; mp 287–289 °C (decomp.).  
1
H NMR (300 MHz, 
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7.93 (d, J = 8.6 Hz, 2H), 7.82 (d, J = 8.6 Hz, 2H), 7.76 (d, J = 8.6 Hz, 2H), 
6.50 (s, 1H), 5.02–4.96 (m, 1H), 3.65–3.25 (m, 4H), 2.44 (s, 3H), 2.27 (s, 3H). 






White solid, 80% yield; mp 228–230 °C. 
1
H NMR (300 MHz, CDCl3):   7.95 
(d, J = 7.8 Hz, 2H), 7.73 (d, J = 7.8 Hz, 2H), 7.64 (d, J = 7.8 Hz, 2H), 7.46 (d, 
J = 7.8 Hz, 2H), 7.40 (s, 1H), 6.77 (t, J = 5.5 Hz, 1H), 6.41 (s, 1H), 5.01–4.92 
(m, 1H), 3.83–3.67 (m, 2H), 3.43 (dd, J = 16.8, 10.7 Hz, 1H), 3.18 (dd, J = 







Pale-yellow solid, 71% yield; mp 245–248 °C (decomp.).  
1
H NMR (300 MHz, 
DMSO-d6):   9.29 (s, 1H), 8.57 (t, J = 5.7 Hz, 1H), 8.30 (d, J = 8.9 Hz, 2H), 
7.92 (d, J = 8.9 Hz, 2H), 7.81–7.74 (m, 4H), 6.27 (s, 2H), 5.93 (s, 1H), 5.01–
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Pale-yellow solid, 73% yield; mp 218–220 °C. 
1
H NMR (300 MHz, DMSO-
d6):   9.24 (s, 1H), 8.56 (t, J = 5.5 Hz, 1H), 7.98 (d, J = 8.2 Hz, 2H), 7.85–
7.76 (m, 6H), 6.25 (s, 2H), 5.94 (s, 1H), 5.00–4.88 (m, 1H), 3.64–3.32 (m, 4H), 







White solid, 74% yield; mp 280–282 °C. 
1
H NMR (300 MHz, DMSO-d6):  
10.26 (s, 1H); 10.03 (s, 1H); 9.85 (s, 1H); 8.56 (t, J = 5.5 Hz, 1H); 8.32 (d, J = 
8.4 Hz, 2H); 7.99–7.93 (m, 4H); 7.80 (d, J = 8.4 Hz, 2H); 7.32 (s, 1H); 5.15–
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White solid, 73% yield; mp 235–237 °C. 
1
H NMR (300 MHz, DMSO-d6):  
10.25 (s, 1H); 10.02 (s, 1H); 9.83 (s, 1H); 8.59 (t, J = 5.5 Hz, 1H); 8.03–7.91 
(m, 4H); 7.86–7.71 (m, 4H); 7.30 (s, 1H); 5.06–4.79 (m, 1H); 3.72–3.43 (m, 







To a suspension of 18a (0.21 g, 0.40 mmol) in EtOH  (6.7 mL), 7.7 mL of 
NaOH 1M were added. The mixture was stirred at reflux for 4h, then H2O (30 
ml) was added and the solution was acidified with diluted H3PO4 to pH 4-5. 
The aqueous phase was washed with EtOAc (3 x 10 ml) and basified with 
NaOH 2N. The suspension was filtered off to recover the pale-yellow solid 
(0.12 g, 70%).; mp 227–229 °C. 
1
H NMR (300 MHz, DMSO-d6):  8.81 (s, 
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2H); 7.79–7.61 (m, 4H); 5.71 (br s, 2H); 5.87 (br s, 2H); 5.23 (s, 1H); 5.07–
4.81 (m, 1H);  3.67–3.40 (m, 4H). ESI-MS m/z: 449 (M+H)
+
. 
Synthesis of tert-butyl 4-(5-((4-((2,6-diaminopyrimidin-4-
yl)amino)benzamido)methyl)-4,5-dihydroisoxazol-3-yl)benzoate and its 
acid (19b and 19c) 
To a suspension of 18b (0.21 g, 0.40 mmol) in EtOH  (6.7 mL), 7.7 mL of 
NaOH 1M were added. The mixture was stirred at room temperature for 4h, 
then H2O (30 ml) was added and the solution was acidified with diluted H3PO4 
to pH 4-5. The aqueous phase was extracted with EtOAc (3 x 10 ml), dried 
(Na2SO4), and filtered. The solvent was concentrated in vacuo and the residue 





White solid, 43% yield; mp 206–208 °C. 
1
H NMR (300 MHz, DMSO-d6):  
8.84 (s, 1H); 8.50 (t, J = 5.1 Hz, 1H); 7.96 (d, J = 8.2 Hz, 2H); 7.77 (d, J = 8.2 
Hz, 2H); 7.75 – 7.62 (m, 4H); 5.92 (br s, 2H); 5.77 (br s, 2H); 5.24 (s, 1H); 
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Derivative 19c is obtained by partial hydrolisis of tert-butyl ester 19b during 
the deprotection reaction. The product was recovered by acidification of the 
aqueous phase with HCl 1N and filtration of the white precipitate (40%); mp 
283–285 °C. 
1
H NMR (300 MHz, DMSO-d6):  13.14 (s, 1H); 11.47 (s,1H); 
9.90 (s,1H); 8.67 (t, J = 5.3 Hz, 1H); 8.00 (d, J = 8.2 Hz, 2H); 7.80 (dd, J = 
13.9, 8.2 Hz, 4H); 7.68 (d, J = 8.2 Hz, 2H); 7.60 (br s, 2H); 7.41 (br s, 2H); 




yl)amino)benzamido)methyl)-4,5-dihydroisoxazol-3-yl)benzoic acid (17c) 
 
A mixture of TFA and DCM (1:3, 8 mL) was added to compound 17b (60 mg, 
0.12 mmol). The reaction was stirred at room temperature overnight and then 
concentrated in vacuo to give the title compound as a white solid (50 mg, 
99%) which was recrystallized from ethanol/Et2O. Mp 295–298 °C (decomp.). 
1
H NMR (300 MHz, DMSO-d6):  10.78 (br s, 1H), 8.72 (t, J = 5.2 Hz, 1H); 
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1H); 5.09–4.80 (m, 1H), 3.67–3.43 (m, 4H), 2.55 (s, 3H); 2.41 (s, 3H). ESI-




yl)amino)benzamido)methyl)-4,5-dihydroisoxazol-3-yl)benzoic acid (18c) 
 
A mixture of TFA and DCM (1:3, 9 mL) was added to compound 18b (70 mg, 
0.14 mmol). The reaction was stirred at room temperature overnight and then 
concentrated in vacuo to give the title compound as a white solid (50 mg, 
99%) which was recrystallized from ethanol/Et2O. Mp 255–258 °C (decomp.). 
1
H NMR (300 MHz, DMSO-d6):  10.50 (br s, 1H), 8.72 (t, J = 5.2 Hz, 1H); 
8.00 (d, J = 8.2 Hz, 2H), 7.85 (dd, J = 13.9, 8.1 Hz, 4H), 7.78 (d, J = 8.2 Hz, 
2H), 6.15 (s, 1H); 5.17–4.77 (m, 1H), 3.77–3.39 (m, 4H), 2.29 (s, 3H). ESI-
MS m/z: 447 (M+H)
+
. 
General procedure for the synthesis of 2,6-substituted-N-((3-(4-
substitutedphenyl)-4,5-dihydroisoxazol-5-yl)methyl)pyrimidin-4-amine 
(20-21) 
The proper amine 15 (0.36 mmol) and 6-chloropyrimidine (0.30 mmol) were 
dissolved in 2-propanol (3 mL) at room temperature in a 3 CEM pressure 
vessels equipped with a stirrer bar. The vials were sealed and heated in a CEM 
Discover microwave synthesizer to 180 °C (measured by the vertically 
focused IR temperature sensor) for 30 min. The solvent was evaporated, the 
crude material was taken up with EtOAc (20 mL), washed with  NaHCO3 
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filtered and concentrated in vacuo. The residue was purified by silica gel 




Pale-yellow solid, 80% yield; mp 129–131 °C. 
1
H NMR (300 MHz, CDCl3): δ 
8.26 (d, J = 8.6 Hz, 2H); 7.80 (d, J = 8.6 Hz, 2H); 6.05 (s, 1H); 5.11–5.06 (m, 
1H); 5.03–4.98 (m, 1H); 3.79–3.72 (m, 2H); 3.45 (dd, J = 16.7, 10.6 Hz, 1H); 







Pale-yellow solid, 80% yield; mp 135–138 °C. 
1
H NMR (300 MHz, CDCl3): δ 
8.01 (d, J = 7.9 Hz, 2H); 7.68 (d, J = 7.9 Hz, 2H); 6.05 (s, 1H); 5.13–4.82 (m, 
2H); 3.88–3.60 (m, 2H); 3.45 (dd, J = 16.2, 10.7 Hz, 1H); 3.18 (dd, J = 17.0, 
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Pale-yellow solid, 70% yield; mp159–162 °C. 
1
H NMR (300 MHz, CDCl3): δ 
8.26 (d, J = 8.6 Hz, 2H); 7.81 (d, J = 8.6 Hz, 2H); 5.66 (s, 1H); 5.14–5.00 (m, 
3H); 4.87–4.98 (m, 1H); 3.76–3.69 (m, 2H); 3.43 (dd, J = 16.8, 10.7 Hz, 1H); 






Pale-yellow solid, 67% yield; mp 128–130 °C. 
1
H NMR (300 MHz, CDCl3): δ 
7.98 (d, J = 8.1 Hz, 2H); 7.66 (d, J = 8.1 Hz, 2H); 5.67 (s, 1H); 5.51–5.36 (m, 
1H), 5.26–5.12 (m, 2H); 5.06–4.90 (m, 1H); 3.87–3.59 (m, 2H); 3.40 (dd, J = 
16.7, 10.7 Hz, 1H); 3.16 (dd, J = 16.8, 7.5 Hz, 1H); 2.18 (s, 3H); 1.59 (s, 9H). 
ESI-MS m/z: 384 (M+H)
+
. 
General procedure for the synthesis of the acids 20c and 21c 
A mixture of TFA and DCM (1:3, 9 mL) was added to compounds 20-21 (0.18 
mmol). The reaction was stirred at room temperature overnight and then 
concentrated in vacuo to give the title compound as a white solid, which was 
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White solid, 99% yield; mp 204–207 °C. 
1
H NMR (300 MHz, DMSO-d6):  
9.24 (br s, 1H); 8.01 (d, J = 8.2 Hz, 2H); 7.78 (d, J = 8.2 Hz, 2H); 6.49 (s, 1H); 
5.05–4.90 (m, 1H); 3.85–3.65 (m, 1H); 3.60–3.48 (m, 4H); 2.48 (s, 3H); 2.33 






White solid, 99% yield; mp 208–210 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 
8.86 (t, J = 5.0 Hz, 1H); 8.01 (d, J = 8.2 Hz, 2H); 7.78 (d, J = 8.2 Hz, 2H); 
7.83–7.25 (m, 2H); 5.95 (s, 1H); 5.15–4.67 (m, 1H); 3.74–3.42 (m, 3H); 3.23 
(dd, J = 17.2, 7.2 Hz, 1H); 2.19 (s, 3H). ESI-MS m/z: 328 (M+H)
+
. 
7.2. Synthesis of NSC derivatives 
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A suspension of phenylhydrazine hydrochloride (4.00 g, 27.7 mmol) and 
diethyl 4-oxopimelate (6.44 g, 27.9 mmol) was heated in toluene (35 mL) 
under N2 in a Dean-Stark apparatus until the full consumption of the starting 
material. After evaporation of the solvent, the residue was purified by flash 
chromatography on silica gel (CH2Cl2) to afford the pyridazinone 28 (6.84 g, 
90%). Yellowish viscous oil.  
1
H NMR (300 MHz, CDCl3): δ 7.49 (d, J = 8.0 
Hz, 2H); 7.36 (t, J = 8.0 Hz, 2H); 7.21 (t, J = 8.0 Hz, 1H); 4.11 (q, J = 7.0 Hz, 
2H); 2.71–2.59 (m, 8H); 1.23 (t, J = 7.0 Hz, 3H). ESI-MS m/z: 275 (M+H)
+
. 
Synthesis of methyl 3-(3-methoxycarbonylmethyl-1H-indol-2-
yl)propanoate (29) 
 
A solution of 28 (3.13 g, 11.41 mmol) in methanol (50 mL) saturated with HCl 
gas was heated under reflux with continuous bubbling of HCl for 2h. After 
evaporation of solvent, the residue was dissolved in CH2Cl2 (50 mL), washed 
with H2O (30 mL), Na2CO3 aqueous saturated solution (30 mL), dried 
(Na2SO4) and evaporated to dryness under reduced pressure. The residue was 
filtered through a short silica gel pad (CH2Cl2) to give the diester 29 (2.54 g, 
81%). White cristals; mp (Et2O) 73–74 °C. 
1
H NMR (300 MHz, CDCl3): δ 
8.61 (s, 1H); 7.54 (d, J = 8.0 Hz, 1H); 7.25 (d, J = 8.0 Hz, 1H); 7.13 (t, J = 8.0 
Hz, 1H); 7.07 (t, J = 8.0 Hz, 1H); 3.69 (s, 1H); 3.68 (s, 1H); 3.63 (s, 3H); 3.04 
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Synthesis of 3-(3-methoxycarbonylmethyl-1H-indol-2-yl)propanoic acid 
(30) 
 
To a solution of ester 29 (0.07 g, 0.25 mmol) in MeOH (0.5 mL), 0.5 mL of 
NaOH 1N were added. The solution was stirred for 3h at room temperature. 
The crude material was concentrated in vacuo and the acqueous phase was 
washed with Et2O (3 x 10 mL). The residue was acidified with HCl 2N. The 
white precipitate was filtered to obtain the pure product. Glossy white crystals, 
99% yield; mp 186–188 °C. 
1
H NMR (300 MHz, CDCl3): δ 12.47 (br s, 2H); 
10.84 (s, 1H); 7.45 (d, J = 8.0 Hz, 1H); 7.31 (d, J = 8.0 Hz, 1H); 7.06 (t, J = 
8.0 Hz, 1H); 6.98 (t, J = 8.0 Hz, 1H); 3.65 (s, 2H); 2.98 (t, J = 7.7 Hz, 2H); 
2.64 (t, J = 7.7 Hz, 2H). ESI-MS m/z: 234 (M+H)
+
. 
Synthesis of ethyl 2-amino-5-oxo-5-(p-tolyl)pentanoate (31) 
 
A solution of DIPEA (0.39 mL, 2.74 mmol) in dry THF (6 mL) was prepared 
and cooled to -78 °C, then BuLi (1.6 M sol., 1.72 mL) and DMPU (0.83 mL, 
6.85 mmol) were added. After 10 min, a solution of ethyl 2-
((diphenylmethylene)amino)acetate (0.73 g, 2.74 mmol) in dry THF (6 mL) 
was added. After further 10 min, a solution of 3-chloro-1-(p-tolyl)propan-1-
one (0.50 g, 2.74 mmol) in dry THF (4 mL) was added, and the mixture was 
stirred at -78 °C. After 2h, the mixture was quenched with NH4Cl saturated 
aqueous solution (50 mL) and extracted with CH2Cl2 (3 x 50 mL). The organic 
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mixture was dissolved in Et2O (5 mL) and 5 mL of HCl 2N were added. The 
solution was basified with solid K2CO3 and extracted with EtOAc (3 x 20 mL). 
The organic phase was dried, filtered and concentrated in vacuoto obtain the 
derivative 31 (0.41 g, 60%). White solid, mp (hexane) 49–50 °C. 
1
H NMR 
(300 MHz, CDCl3): δ 7.80 (d, J = 7.4 Hz, 2H); 7.24 (d, J = 7.4 Hz, 2H); 4.16 
(q, J = 5.9 Hz, 2H); 3.81 (t, J = 7.6 Hz, 1H); 2.86 (t, J = 5.9 Hz, 2H); 2.35 (s, 
3H); 2.13 (dq, J = 7.4, 6.1 Hz, 2H); 1.58 (s, 1H); 1.49 (s, 1H); 1.33 (t, J = 5.9 
Hz, 3H). ESI-MS m/z: 250 (M+H)
+
. 
Synthesis of ethyl 2-amino-5-oxo-5-(p-tolyl)pentanoate (32) 
 
To a solution of 31 (0.41 g, 1.64 mmol) in dry CH2Cl2 (20 mL), acetic 
anhydride (0.77 mL, 8.20 mmol) was added and the reaction was stirred at 
reflux. After 4h, 20 mL of HCl 1N were added and the mixture was extracted 
with CH2Cl2 (3 x 20 mL), dried (Na2SO4), filtered and concentrated in vacuoto 
have the desired product 32. White solid, 99% yield; mp 90–92 °C. 
1
H NMR 
(300 MHz, CDCl3): δ 7.78 (d, J = 7.5 Hz, 2H); 7.23 (d, J = 7.4 Hz, 2H); 5.86 
(s, 1H); 4.60 (t, J = 7.5 Hz, 1H); 4.19 (q, J = 6.0 Hz, 2H); 2.82 (t, J = 8.1 Hz, 
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After the dissolution of 32 (0.46 g, 1.60 mmol) in EtOH (2.5 mL), H2O (2.5 
mL) and Amb. 900 OH (2 equiv) were added. After 3h at room temperature, 
the resin was filtered off, washed with EtOH and H2O, then suspended in HCl 
1N. After 30 min at room temperature, the suspension was filtered and the 
filtrate was concentrated in vacuo and lyophilized to obtain derivative 34. 
White solid, 99 % yield; mp 150–152 °C; free base. 
1
H NMR (300 MHz, 
DMSO-d6): δ 7.75 (d, J = 7.5 Hz, 2H);  7.24 (d, J = 7.5 Hz, 2H); 3.44 (t, J = 
7.8 Hz, 1H); 2.79 (t, J = 5.9 Hz, 2H); 2.46 (s, 1H); 2.33 (s, 1H); 2.05 (s, 1H); 
2.03–1.89 (m, 2H). ESI-MS m/z: 222 (M+H)
+
. 
Synthesis of methyl 2-(4-nitrophenylsulfonamido)acetate (35) 
 
To a solution of 4-nitrobenzene-1-sulfonyl chloride (0.58 g, 2.63 mmol) and 
GlyOMeHCl (0.30 g, 2.39 mmol) in dry CH2Cl2 (13 mL), triethylamine (1.2 
mL, 8.60 mmol) was added and the mixture was stirred at room temperature 
for 1.5h. the organic phase was washed with HCl 1N (3x 10 mL), NaHCO3 
aqueous saturated solution (3 x 10 mL) and brine (1 x 10 mL). The organic 
phase was dried (Na2SO4), filtered and concentrated in vacuo to give the pure 
product (0.41 g, 57%). White solid; mp (CH2Cl2/hexane): 87– 89 °C. 
1
H NMR 
(300 MHz, CDCl3): δ 8.44 (d, J = 7.4 Hz, 2H); 8.22 (d, J = 7.4 Hz, 2H); 5.23 
(s, 1H); 4.07 (d, J = 19.0 Hz, 2H); 3.76 (s, 3H). ESI-MS m/z: 275 (M+H)
+
. 
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Pd/C (5 wt % palladium on activated carbon, 0.1 eq) was added to a solution 
of 35 (0.31 g, 1.14 mmol) in EtOH (180 mL), and the reaction was stirred 
under 1 atm of H2 (balloon) for 2h. The reaction mixture was filtered and, after 
solvent evaporation, a colourless oil was recollected (0.27 g, 99%). 
1
H NMR 
(300 MHz, CDCl3): δ 7.73 (d, J = 7.4 Hz, 2H); 6.86 (d, J = 7.5 Hz, 2H); 5.60 




Synthesis of methyl 2-(4-(4-
methoxybenzamido)phenylsulfonamido)acetate (37) 
 
A solution of 4-methoxybenzoic acid (0.10 g, 1.25 mmol) in thionyl chloride 
(5 mL) was refluxed for 2h under nitrogen atmosphere. After cooling at room 
temperature, the excess thionyl chloride was removed at reduced pressure and 
the crude material dried under vacuum. To the residue, dissolved in dry THF 
(5 mL) and cooled to 0 °C, a mixture of the amine 36 (0.27 g, 1.14 mmol) and 
triethylamine (0.17 mL, 1.25 mmol) in dry THF (5 mL) was added dropwise. 
The reaction mixture was stirred at room temperature for 12h, filtered and 
evaporated. The residue was taken up with EtOAc (20 mL) and washed with 
NaHCO3 saturated aqueous solution (2 × 20 mL) and brine (20 mL). The 
organic phase was dried (Na2SO4), filtered, and concentrated in vacuo to give 
the title compound (0.33 g, 77%) as a white solid. Mp (MeOH/Et2O) 150– 152 
°C. 
1
H NMR (300 MHz, CDCl3): δ 8.39 (s, 1H); 8.07 (d, J = 7.4 Hz, 2H); 7.84 
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Synthesis of 2-(4-(4-methoxybenzamido)phenylsulfonamido)acetic acid 
(38) 
 
To a suspension on 37 (0.15 g, 0.39 mmol) in MeOH (10 mL), a solution of 
LiOH (0.04 g, 1.54 mmol) in H2O (10 mL) was added and stirred at room 
temperature. After 2.5h, the solvent was removed under reduced pressure, 
taken up with water and washed with CH2Cl2 (3 x 10 mL). The aqueous phase 
was acidified with HCl 6N to pH 1. The white precipitate was filtered to 
recover the pure compound. White solid (0.13 g, 90%); mp 178–180 °C. 
1
H 
NMR (300 MHz, DMSO-d6): δ 10.46 (s, 1H); 10.20 (s, 1H); 8.04 (d, J = 7.5 
Hz, 2H); 7.84 (d, J = 7.5 Hz, 2H); 7.72 (d, J = 7.5 Hz, 2H); 7.04 (d, J = 7.4 Hz, 




Synthesis of 3-(4-nitrophenylsulfonamido)propanoic acid (39) 
 
To a cold solution (0 °C) of -Alanine (0.30 g, 3.37 mmol) in 1M NaOH (3.5 
mL) was added 4-nitrobenzylsulfonyl chloride (0.75 g, 3.37 mmol). The 
reaction mixture was stirred for 3 h at room temperature. The pH was kept at 
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aqueous phase was adjusted to 2 by the addition of 1N HCl. This solution was 
extracted with EtOAc (3 x 20 mL). The combined organic phases were washed 
with H2O and brine. The organic layer was then dried (Na2SO4) and the excess 
solvent removed under reduced pressure. The product (0.35 g, 37%) was 
afforded as a white solid. Mp: 154–155 °C. 
1
H NMR (300 MHz, CDCl3): δ 
9.50 (s, 1H); 8.40 (d, J = 7.4 Hz, 2H); 8.22 (d, J = 7.5 Hz, 2H); 6.00 (s, 1H); 
3.49 (t, J = 5.3 Hz, 1H); 3.43 (t, J = 5.3 Hz, 1H); 2.52 (t, J = 5.3 Hz, 2H). ESI-
MS m/z: 275 (M+H)
+
. 
Synthesis of 3-(4-aminophenylsulfonamido)propanoic acid (40) 
 
Pd/C (5 wt % palladium on activated carbon, 0.1 eq) was added to a solution 
of 39 (0.35 g, 1.26 mmol) in EtOH (180 mL), and the reaction was stirred 
under 1 atm of H2 (balloon) for 2h. The reaction mixture was filtered and, after 
solvent evaporation, a colourless oil was recollected (0.30 g, 99%). 
1
H NMR 
(300 MHz, CDCl3): δ 9.51 (s, 1H); 7.74 (d, J = 7.5 Hz, 2H); 6.86 (d, J = 7.5 
Hz, 2H); 5.66 (s, 2H); 4.28 (s, 1H); 3.55 (t, J = 7.9 Hz, 1H); 3.46 (t, J = 7.9 Hz, 
1H); 2.57 (t, J = 7.9 Hz, 2H). ESI-MS m/z: 245 (M+H)
+
. 
Synthesis of 3-(4-benzamidophenylsulfonamido)propanoic acid (41) 
 
A solution of benzoic acid (0.08 g, 0.69 mmol) in thionyl chloride (4 mL) was 
refluxed for 2h under nitrogen atmosphere. After cooling at room temperature, 
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material dried under vacuum. To the residue, dissolved in THF (4 mL) and 
cooled to 0 °C, a mixture of the amine 40 (0.30 g, 1.26 mmol) in THF (4 mL) 
and NaHCO3 (0.11 mL, 1.26 mmol) in H2O (8 mL) was added dropwise. The 
reaction mixture was stirred at reflux for 48 h and evaporated. The residue was 
taken up with NaOH 2N to pH 10 and washed with EtOAc (3 × 20 mL). The 
aqueous phase was acidified with HCl 3N to pH 2 and the solid was filtered to 
obtain the pure product (0.17 g, 70%) as a white solid. Mp 185– 187 °C. 
1
H 
NMR (300 MHz, DMSO-d6): δ 10.87 (s, 1H); 9.77 (s, 1H); 8.07 (d, J = 7.5 Hz, 
2H); 7.93–7.80 (m, 2H); 7.61 (d, J = 7.4 Hz, 2H); 7.53–7.31 (m, 3H); 5.27 (s, 
1H); 3.57 (t, J = 5.6 Hz, 1H); 3.49 (t, J = 5.6 Hz, 1H); 3.49 (t, J = 5.6 Hz, 1H). 
ESI-MS m/z: 349 (M+H)
+
. 
Synthesis of (R)-2-amino-5-methoxy-5-oxopentanoic acid hydrochloride 
(42) 
 
To a cooled suspension (-10 °C) of D-glutamic acid (1.00 g, 6.80 mmol) in 
MeOH (5 mL) thionyl chloride (0.76 mL, 10.9 mmol) was added dropwise. 
The mixture was stirred at room temperature for 30 min, then Et2O (20 mL) 
was added. The white precipitate was filtered to obtain the pure product (1.34 
g, 99%). Mp 257–259 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 12.34 (s, 1H); 
3.80 (s, 3H); 3.22 (t, J = 7.4 Hz, 1H); 2.44 (t, J = 7.9 Hz, 2H); 2.24–2.07 (m, 
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Synthesis of (S)-2-(1,3-dioxoisoindolin-2-yl)-5-methoxy-5-oxopentanoic 
acid (43) 
 
To a solution of 42 (1.00 g, 5.06 mmol) in 0.55 mol/l aqueous Na2CO3 (20 
mL, 11.13 mmol) was added N-ethoxycarbonylphtalimide (1.60 g, 7.33 mmol) 
at 0 °C. the reaction mixture was stirred at 0 °C for 10 min and at room 
temperature for 50 min, then insoluble material was removed by filtration and 
HCl 2N was added to the filtrate ultil the pH reached about 2. Then the 
mixture was stirred at 0 °C for 30 min, the solution was extracted with EtOAc 
(2 x 50 mL). The organic phase was dried (Na2SO4), filtered and concentrated 
in vacuo to afford the desired compound (1.47 g, 99%). White solid, mp 102– 
104 °C. 
1
H NMR (300 MHz, CDCl3): δ 9.13 (s, 1H); 8.02–7.63 (m, 2H); 7.63–
7.30 (m, 2H); 4.78 (t, J = 3.1 Hz, 1H); 3.82 (s, 3H); 2.50–2.37 (m, 2H); 2.35–
2.20 (m, 2H). ESI-MS m/z: 292 (M+H)
+
. 
Synthesis of (S)-methyl 5-amino-4-(1,3-dioxoisoindolin-2-yl)-5-
oxopentanoate (44)  
 
To a cooled solution (-10 °C) of 43 (0.15 g, 0.51 mmol) in THF (2 mL), NMM 
(56.0 µL, 0.51 mmol), isobutyl chloroformate (78.0 µL, 0.76 mmol) and NH3 
were added. The reaction was stirred 30 min at -10 °C and 1h at room 
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added and extracted with EtOAc (3 x 20 mL). The organic phase was washed 
with 5% NaHCO3 solution (1 x 20 mL) and H2O (1 x 20 mL). The crude 
mixture was purified by silica gel chromatography (cyclohexane/EtOAc) to 
obtain the pure product (0.07 g, 51%). White solid, mp 96– 98 °C. 
1
H NMR 
(300 MHz, CDCl3): δ 7.83–7.70 (m, 2H); 7.70–7.43 (m, 2H); 5.13 (s, 2H); 




Synthesis of (S)-5-amino-4-(1,3-dioxoisoindolin-2-yl)-5-oxopentanoic acid 
(45)  
 
Derivative 44 (0.05 g, 0.17 mmol) was dissolved in HCl 2N in dioxane (85.0 
µL) and stirred at room temperature overnight. The solution was concentrated 
in vacuo to obtain the final product (0.04 g, 99%) as a white solid. Mp 119– 
121°C. 
1
H NMR (300 MHz, DMSO-d6): δ 12.04 (s, 1H); 7.83–7.88 (m, 4H); 
7.57 (s, 1H); 7.16 (s, 1H); 4.56 (dd, J = 10.3, 4.3 Hz, 1H); 2.37–2.29 (m, 1H); 
2.20–1.09 (m, 3H). ESI-MS m/z: 277 (M+H)
+
. 
General synthesis of 1-(-carboxyalkyl)-1-carbethoxy-2,3-
dioxopyrrolidines (46, 49) 
To a cooled stirred solution of amino acid (29.1 mmol) in ethanolic sodium 
ethoxide (25 mL, 29.1 mmol) was added ethyl acrylate (29.1 mmol) in small 
portions and the mixture was stirred overnight. The resulting solution of the 
adduct was heated with an ethanolic sodium ethoxide solution (10 mL, 29.1 
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reaction mixture was poured into ice-cold water and acidified with 




White solid, 52% yield; mp 182–186 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 
11.25 (s, 1H); 4.15 (q, J = 7.1 Hz , 2H); 3.95 (s, 2H); 3.39 (t, J = 6.9 Hz, 2H); 







White solid, 66% yield; mp 195–200 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 
11.25 (s, 1H); 4.11 (q, J = 7.1 Hz, 2H); 3.93 (s, 2H); 3.54 (t, J = 6.9 Hz, 2H); 
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White solid, 60% yield; mp 118–120 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 
11.25 (s, 1H); 4.16 (q, J = 7.1 Hz, 2H); 3.95 (s, 2H); 3.38 (t, J = 12.1 Hz, 2H); 




General procedure for the synthesis of 4-arylidene-1-(-carboxyalkyl)-
3,4-dioxopyrrolidines  (47, 50a-h) 
The 1-(-carboxyalkyl)-1-carbethoxy-2,3-dioxopyrrolidine (10.0 mmol) was 
refluxed with HCl 6N (50 mL) for 30 min. To the solution was added 
dropwise the aromatic aldehyde (15.0 mmol) in 5 mL of formic acid. The 
mixture was refluxed for an additional 2.5h. The solution was poured onto 
crushed ice and the precipitate solid was collected by filtration and washed 
with water.  
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White solid, 43% yield; mp 206–207 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 
7.71 (d, J = 7.9 Hz, 2H), 7.59 (d, J = 7.9 Hz, 2H), 7.54 (s, 1H), 4.64 (s, 2H), 






50a: 3-(4-(4-methoxybenzylidene)-2,3-dioxopyrrolidin-1-yl)propanoic acid 
 
Yellow solid, 71% yield; mp 236–240 °C (decomp). 
1
H NMR (300 MHz, 
DMSO-d6): δ 7.66 (d, J = 7.8 Hz, 2H); 7.53 (s, 1H); 7.09 (d, J = 8.0 Hz, 2H); 
4.65 (s, 2H); 3.89 (s, 3H); 3.70 (t, J = 7.0 Hz, 2H); 2.67 (t, J = 7.1 Hz, 2H). 






Yellow solid, 86% yield; mp 298–300 °C (decomp). 
1
H NMR (300 MHz, 
DMSO-d6): δ 8.02 (d, J = 9.3 Hz, 2H), 7.80 (d, J = 9.3 Hz, 2H), 7.56 (s, 1H), 
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50c: 3-(4-(4-chlorobenzylidene)-2,3-dioxopyrrolidin-1-yl)propanoic acid 
 
Yellow solid, 66% yield; mp 200–202 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 
7.71 (d, J = 7.9 Hz, 2H), 7.59 (d, J = 7.9 Hz, 2H), 7.54 (s, 1H), 4.64 (s, 2H), 






50d: 4-(4-(4-methoxybenzylidene)-2,3-dioxopyrrolidin-1-yl)butanoic acid 
 
Yellow solid, 43% yield; mp 194–197 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 
7.67 (d, J = 8.7 Hz, 2H); 7.52 (s, 1H), 7.08 (d, J = 8.7 Hz, 2H), 4.58 (s, 2H); 
3.84 (s, 3H); 3.52 (t, J = 6.9 Hz, 2H); 2.28 (t, J = 7.2 Hz, 2H); 1.93-1.84 (m, 
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Yellow solid, 60% yield; mp 272–276 °C (decomp). 
1
H NMR (300 MHz, 
DMSO-d6): δ 8.03 (d, J = 8.3 Hz, 2H); 7.80 (d, J = 8.3 Hz, 2H); 7.60 (s, 1H); 
4.65 (s, 2H); 3.53 (t, J = 7.0 Hz, 2H); 2.30 (t, J = 7.0 Hz, 2H); 1.89 (m, J = 
1.92-1.87 Hz, 2H). ESI-MS m/z: 318 (M+H)
+
. 
50f: 5-(4-(4-methoxybenzylidene)-2,3-dioxopyrrolidin-1-yl)pentanoic acid 
 
Yellow solid, 30% yield; mp 148–150 °C (decomp). 
1
H NMR (300 MHz, 
DMSO-d6): δ 7.67 (d, J = 8.7 Hz, 2H); 7.51 (s, 1H); 7.08 (d, J = 8.7 Hz, 2H); 
4.58 (s, 2H); 3.85 (s, 3H); 3.50 (t, J = 6.8 Hz, 2H); 2.27 (t, J = 7.2 Hz, 2H); 
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Yellow solid, 60% yield; mp 270–273 °C (decomp). 
1
H NMR (300 MHz, 
DMSO-d6): δ 8.01 (d, J = 8.2 Hz, 2H); 7.80 (d, J = 8.2 Hz, 2H); 7.58 (s, 1H); 
4.65 (s, 2H); 3.49 (t, J = 6.9 Hz, 2H); 2.27 (t, J = 7.1 Hz, 2H); 1.79-1.40 (m, 
4H). ESI-MS m/z: 332 (M+H)
+
. 
50h: 5-(4-(4-chlorobenzylidene)-2,3-dioxopyrrolidin-1-yl)pentanoic acid 
 
Yellow solid, 38% yield; mp 210–212 °C (decomp). 
1
H NMR (300 MHz, 
DMSO-d6): δ 7.73 (d, J = 7.3 Hz,2H); 7.60 (s, 1H); 7.56 (d, J = 7.3 Hz, 2H); 
4.61 (s, 2H); 3.47 (t, J =  7.1 Hz, 2H); 2.26 (t, J = 7.1 Hz,  2H); 1.72–1.60 (m, 
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General procedure for the synthesis of 2-amino-4-aryl-6-(-
carboxyalkyl)-5H-pyrrolo[3,4-d]pyrimidin-7-(6H)ones (48 and 51a-h) 
A solution of guanidine in absolute ethanol was prepares by addition of 3.80 g 
(40.0 mmol) of guanidine hydrochloride to 100 mL of 0.4N ethanolic sodium 
ethoxide, followed by filtration to remove precipitated sodium chloride. A 10 
mmol quantity of the benzylidene compound (47 or 49) and 0.50 g of 
guanidine hydrochloride were added and the mixture was stirred for 72h at 
room temperature. The solution was cooled in an ice bath and the product was 
collected by filtration, then dissolved in 20 mL of water. Following 
precipitation by dropwise addition of 50% acetic acid, the product was 




White solid, 30% yield; mp 253–255 °C. 
1
H NMR (300 MHz, D2O/NaOD): δ 
7.36 (d, J = 8.0 Hz, 2H); 7.18 (d, J = 8.0 Hz, 2H); 3.70 (t, J = 6.4 Hz, 2H); 2.51 
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Yellow solid, 35% yield; mp 218–220 °C. 
1
H NMR (300 MHz, D2O/NaOD): δ 
7.38 (d, J = 8.0 Hz , 2H); 6.68 (d, J = 8.0 Hz, 2H); 3.75 (s, 3H); 3.69 (t, J = 6.2 






Yellow solid, 34% yield; mp 275–277 °C. 
1
H NMR (300 MHz, D2O/NaOD): δ 
7.99 (d, J = 8.2 Hz, 2H); 7.88 (d, J = 8.2 Hz, 2H); 3.86 (t, J = 7.0 Hz, 2H); 2.58 
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White solid, 37% yield; mp 232–234 °C. 
1
H NMR (300 MHz, D2O/NaOD): δ 
7.36 (d, J = 8.0 Hz, 2H); 7.18 (d, J = 8.0 Hz, 2H); 3.70 (t, J = 6.4 Hz, 2H); 2.51 








Yellow solid, 30% yield; mp 236–240 °C. 
1
H NMR (300 MHz, DMSO-d6): δ 
12.06 (s, 1H); 7.98 (d, J = 8.6 Hz, 2H); 7.11 (d, J = 8.6 Hz, 2H); 6.91 (s, 2H); 
4.68 (s, 2H); 3.85 (s, 3H); 3.55 (t, J = 7.2 Hz, 2H); 2.27 (t, J = 7.1 Hz); 1.92–
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Yellow solid, 34% yield; mp 292–296 °C. 
1
H NMR (300 MHz, D2O/NaOD): δ 
7.97 (d, J = 8.1 Hz, 2H); 7.84 (d, J = 8.1 Hz, 2H); 3.61 (t, J = 7.1 Hz, 2H); 2.20 








Yellow solid, 38% yield; mp 243–245 °C. 
1
H NMR (300 MHz, D2O/NaOD): δ 
7.69 (d, J = 8.0 Hz, 2H); 6.97 (d, J = 8.0 Hz, 2H); 3.87 (s, 3H); 3.60 (t, J = 6.9 
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Yellow solid, 37% yield; mp 301–303 °C. 
1
H NMR (300 MHz, D2O/NaOD): δ 
7.87 (d, J = 8.1 Hz, 2H); 7.72 (d, J = 8.1 Hz, 2H); 3.47 (t, J = 6.9 Hz, 2H); 2.13 








Yellow solid, 32% yield; mp 260–262 °C. 
1
H NMR (300 MHz, D2O/NaOD): δ 
7.56 (d, J = 7.9 Hz , 2H); 7.36 (d, J = 7.9 Hz, 2H); 3.54 (t, J = 5.6 Hz, 2H); 
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7.3. Synthesis of 4-aryl-2-butanones (52-53) 
Microwave and Continuous Flow Equipment. Microwave irradiation 
experiments were carried out in Pyrex or silicon carbide (SiC) process vials in 
an Anton Paar Monowave 300 single-mode microwave instrument (IR and/or 
internal fiberoptic temperature monitoring). Laboratory scale flow 
experiments were performed using a FlowSyn (Uniqsis), or X-Cube Flash/H-
Cube (ThalesNano Nanotechnology Inc.) flow reactors.  
Synthesis of 4-(6-methoxynaphthalen-2-yl)-3-buten-2-one (52a).  
 
Batch Microwave Synthesis: Wittig Reaction. To a solution of 
(acetylmethylene)triphenylphosphorane 56 (0.19 g, 0.61 mmol) in 3 mL of 
DMF, 6-methoxy-2-naphthaldehyde 55a (0.07 g, 0.36 mmol) wasadded, and 
the mixture was stirred for 30 s in a 10-mL Pyrex vial. The solution was 
capped with a Teflon septum and heated by microwave irradiation at 210 °C 
for 10 min. After cooling the vessel to ambient conditions, the crude reaction 
mixture was concentrated under reduced pressure and transferred to a silica-
samplet, dried for 1h at 50 °C in a drying oven, and subjected to automated 
flash chromatography with petroleum ether/ethyl acetate (0 to 45% gradient) 
as eluent to provide 0.08 g (94%) of 4-(6-methoxynaphthalen-2-yl)-3-buten-2-
one (52a). Yellow solid, mp 118–120 °C. 
1
H NMR (300 MHz, CDCl3):  
7.89–7.63 (m, 5H); 7.69 (d, J = 16.2 Hz, 1H); 7.19–7.13 (m, 2H); 3.94 (s, 3H); 
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Batch Microwave Synthesis: Aldol Reaction. To a solution of 55a (0.56 g, 2.50 
mmol) in 2 mL of acetone, 60 μL of NaOH 10% solution and 1 mL of distilled 
water were added, and the mixture was stirred for 30 s in a 10 mL Pyrex vial. 
The solution was capped with a Teflon septum and heated by microwave 
irradiation at 70 °C for 450 s. After cooling the vessel to ambient conditions, 
the crude reaction mixture was concentrated under reduced pressure and 
transferred to a silica-samplet, dried for 1h at 50 °C in a drying oven, and 
subjected to automated flash chromatography with petroleum ether/ethyl 
acetate (0 to 45% gradient) as eluent to provide 0.55 g (97%) of 52a identical 
in all respects to the sample prepared above. 
 
Continuous Flow Synthesis: Wittig Reaction. To a solution of 56 (0.65 g, 2.04 
mmol) in 10 mL of DMF, 55a (0.22 g, 1.20 mmol) was added, and the mixture 
was stirred for 30 s in a 15-mL Pyrex vial. At the same time the FlowSyn 
reactor was equipped with a stainless steel reaction coil (10 mL volume, 10 
min residence time at 1 mL/min flow rate). The reaction parameters, 
temperature (210 °C) and 1 mL/min flow rate, were selected on the flow 
reactor, and processing was started, whereby initially only DMF solvent was 
pumped through the system until the instrument had achieved the desired 
reaction parameters and stable processing was achieved. At that point the inlet 
tube was switched from the solvent flask to the 15-mL glass vial containing 
the reaction mixture. After processing through the flow reactor, the inlet flow 
was dipped back into the flask containing solvent and was processed for an 
additional 1min, thus washing from the system any remaining reaction 
mixture. The reaction was concentrated under vacuum, and the product 52a 
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Continuous Flow Synthesis: Aldol Reaction. To a solution of 55a (0.26 g, 1.37 
mmol) in 6.5 mL of acetone were added 33 μL of a 10% aqueous NaOH 
solution and 3.5 mL of distilled water, and the mixture was stirred for 30 s. At 
the same time the FlowSyn reactor was equipped with a stainless steel reaction 
coil (10 mL volume, 450 s residence time at 1.34 mL/min flow rate). The 
reaction parameters, temperature (70 °C) and 1.34 mL/min flow rate, were 
selected on the flow reactor, and processing was started, whereby initially only 
solvent acetone was pumped through the system until the instrument had 
achieved the desired reaction parameters and stable processing was achieved. 
At that point the inlet tube was switched from the solvent flask to the 15-mL 
glass vial containing the freshly prepared reaction mixture (a slow aldol 
condensation occurs also at room temperature). After processing through the 
flow reactor, the inlet flow was dipped back into the flask containing solvent 
and processed for an additional min, thus washing from the system any 
remaining reaction mixture. The reaction was concentrated under vacuum, and 
the product was isolated as described above in 94% yield. 
Synthesis of 4-(6-methoxynaphthalen-2-yl)-butan-2-one (53a). 
 
A 10-mL stock solution of 4-(6-methoxynaphthalen-2-yl)-3-buten-2-one 52a 
of 0.5M concentration in DMF was prepared in a glass vial. The reaction 
parameters (Full-H2 mode, 100 °C and 1mL/min flow rate) were selected on 
the H-Cube hydrogenator. The instrument was fitted with a 30 mm Ra/Ni 
CatCart and the processing was started, whereby initially only pure solvent 
was pumped through the system until the instrument had achieved the desired 
reaction parameters and stable processing was achieved. At that point the 
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reaction volume of 15 mL was collected and the cartridge subsequently 
washed with pure solvent for 5 min to remove any substrate/product still 
adsorbed on the catalyst. Evaporation of the solvent afforded 4-(6-
methoxynaphthalen-2-yl)-butan-2-one (53a) as a colorless oil (97% crude 
yield), which was purified by flash chromatography to provide 1.02 g of pure 
product as a white solid (90%). Mp 77–79 °C. 
1
H NMR (300 MHz, CDCl3): δ 
7.68–7.11 (m, 6H); 3.91 (s, 3H); 3.05–3.00 (m, 2H); 2.86–2.81 (m, 2H); 2.15 
(s, 3H). ESI-MS m/z: 229 (M+H)
+
. 
Synthesis of 4-(4-methoxyphenyl)-3-buten-2-one (52b) 
 
Batch Microwave Synthesis: Mizoraki–Heck Reaction. To 1 mL of DMF/H2O 
(3:1) solvent in a 10 mL Pyrex microwave vial 4-iodoanisole (0.10 g, 0.43 
mmol), methyl vinyl ketone (52.0 μL, 0.64 mmol) and Cs2CO3 (0.15 g, 0.47 
mmol) were added, followed by 2 mL of a 0.0004 M stock solution of 
Pd(OAc)2 in DMF/H2O (3:1) (0.19 mg, 0.2 mol %). The reaction mixture was 
stirred for 30 s, capped with a Teflon septum and subjected to microwave 
heating for 20 min (hold time) at 160 °C. After cooling to ambient 
temperature, the crude reaction mixture was concentrated in vacuo and the 
residue subjected to automated flash chromatography with petroleum 
ether/ethyl acetate (0 to 45% gradient) as eluent to provide 0.06 g (74%) of 
52b. Yellow solid, mp 73–75 °C. 
1
H NMR (300 MHz, CDCl3): δ 7.52–7.45 
(m, 3H); 6.94–6.89 (m, 2H); 6.61 (d, J = 16.2 Hz, 1H); 3.85 (s, 3H); 2.36 (s, 
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Batch Microwave Synthesis: Wittig Reaction. To a solution of 
(acetylmethylene)triphenylphosphorane (0.19 g, 0.61 mmol) in 3 mL of DMF, 
44.0 μL of p-anisaldehyde (0.36 mmol) were added and the mixture was 
stirred for 30 s in a 10 mL Pyrex vial. The solution was capped with a Teflon 
septum and heated by microwave irradiation at 210 °C for 10 min. After 
cooling the vessel to ambient conditions, the crude reaction mixture was 
concentrated in vacuo and transferred to a silica-samplet, dried for 1h at 50 °C 
in a drying oven and subjected to automated flash chromatography with 
petroleum ether/ethyl acetate (0 to 45% gradient) as eluent to provide 0.06 g 
(95%) of 52b in all respects identical to a sample prepared above. 
 
Batch Microwave Synthesis: Aldol Condensation. To a solution of p-
anisaldehyde (0.30 mL, 2.50 mmol) in 2 mL of acetone, were added 60.0 μL 
of NaOH 10% solution and 1 mL of distilled water, and the mixture was 
stirred for 30 s in a 10 mL Pyrex vial. The solution was capped with a Teflon 
septum and heated by microwave irradiation at 120 °C for 1 min. After 
cooling the vessel to ambient conditions, the crude reaction mixture was 
concentrated under reduced pressure and transferred to a silica-samplet, dried 
for 1h at 50 °C in a drying oven and subjected to automated flash 
chromatography with petroleum ether/ethyl acetate (0 to 45% gradient) as 
eluent toprovide 0.41 g (94%) of 52b. 
 
Continuous Flow Synthesis: Mizoroki–Heck Reaction. To a stirred mixture of 
4-iodoanisole (0.33 g, 1.43 mmol), methyl vinyl ketone (0.17 mL, 2.14 mmol), 
Cs2CO3 (0.51 g, 1.57 mmol) and DMF/H2O (3:1) (5 mL) was added 5 mL of a 
0.0008 M stock solution of Pd(OAc)2 in DMF/ H2O (3:1) (0.64 mg, 0.2 mol 
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equipped with a stainless steel reaction coil (16 mL volume, 10 min residence 
time at 1.6 mL/ min flow rate). The reaction parameters temperature (180 °C), 
pressure (60 bar) and 1.6 mL/min flow rate were selected on the flow reactor, 
and processing was started, whereby initially only solvent DMF/H2O (3:1) was 
pumped through the system until the instrument had achieved the desired 
reaction parameters and stable processing was achieved. At that point the inlet 
tube was switched from the solvent flask to the 15-mL glass vial containing 
the reaction mixture. After processing through the flow reactor, the inlet flow 
was dipped back into the flask containing solvent and processed for an 
additional 10 min, thus washing from the system any remaining reaction 
mixture. Workup as above provided 0.17 g (67%) of 52b.  
 
Continuous Flow Synthesis: Wittig Reaction. To a solution of 
(acetylmethylene)triphenylphosphorane (0.65 g, 2.04 mmol) in 10 mL of DMF 
was added 0.13 mL of p-anisaldehyde (1.20 mmol), and the mixture was 
stirred for 30 s in a 15-mL Pyrex vial. At the same time the FlowSyn reactor 
was equipped with a stainless steel reaction coil (10 mL volume, 10 min 
residence time at 1 mL/min flow rate). The reaction parameters temperature 
(210 °C) and 1 mL/min flow rate were selected on the flow reactor, and 
processing was started, whereby initially only solvent DMF was pumped 
through the system until the instrument had achieved the desired reaction 
parameters and stable processing was achieved. At that point the inlet tube was 
switched from the solvent flask to the 15-mL glass vial containing the reaction 
mixture. After processing through the flow reactor, the inlet flow was dipped 
back into the flask containing solvent and processed for an additional 1 min, 
thus washing from the system any remaining reaction mixture. The reaction 
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Continuous Flow Synthesis: Aldol Reaction. To a solution of p-anisaldehyde 
(0.97 mL, 8.00 mmol) in 6.5 mL of acetone were added 0.19 mL of NaOH 
10% solution and 3.5 mL of distilled water and stirred for 30 s. At the same 
time the FlowSyn reactor was equipped with a stainless steel reaction coil (5 
mL volume, 1 min residence time at 5 mL/min flow rate). The reaction 
parameters temperature (120 °C) and 5 mL/min flow rate were selected on the 
flow reactor, and processing was started, whereby initially only acetone 
solvent was pumped through the system until the instrument had achieved the 
desired reaction parameters and stable processing was achieved. At that point 
the inlet tube was switched from the solvent flask to the 15 mL glass vial 
containing the freshly prepared reaction mixture (a slow aldol condensation 
occurs also at room temperature). After processing through the flow reactor, 
the inlet flow was dipped back into the flask containing solvent and processed 
for an additional min, thus washing from the system any remaining reaction 
mixture. The reaction was concentrated under vacuum and 1.27 g (90%) of 
product 52b was isolated as described above. 
Continuous Mesofluidic Flow Synthesis: Aldol Reaction. The flow rate was set 
to 40 g/min (∼45 mL/min). The starting solution was prepared from p-
anisaldehyde (486 mL, 4.0 mol, 4.47 g/min, 0.033 mol/min) and NaOH (96 
mL 10% aqueous solution, 0.2 mol, 0.09 g/min, 0.002 mol/min) in 3.25 L 
acetone (21.08 g/min, 0.36 mol/min) and 1.75 L deionized water (14.37 
g/min). With pure acetone the pressure maintaining valve was adjusted to 7 
bar. Together with 2 bar pressure drop from the residence time tubing an 
overall pressure of 9 bar was achieved. The silicon oil bath was heated to 120 
°C. The process was started by feeding the starting solution into the system 
and putting the residence time tubing into the preheated silicon oil bath. A 
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were collected after 3 and 5.5 min from process start. Then four larger samples 
(∼1.1 L) were collected in about 25 min each (after 8, 33, 58, and 82 min). All 
samples have been analyzed as mentioned previously via HPLC and showed 
full conversion and the same selectivity as achieved in the small-scale 
experiments. A 1.1 L fraction was worked up. The solvent was evaporated, 
and the obtained precipitate was washed with a total volume of 1 L of distilled 
water and subsequently dried in a desiccator under vacuum to give 52b in 
almost quantitative yield. 
Synthesis of 4-(4-methoxyphenyl)-butan-2-one (53b) 
 
A 10 mL stock solution of 52b with a 0.5 M concentration in EtOH was 
prepared in a glass vial. The reaction parameters (Full-H2 mode, room 
temperature and 1.5 mL/min flow rate) were selected on the H-Cube 
hydrogenator. The instrument was fitted with a 30 mm Ra/Ni CatCart and the 
processing was started, whereby initially only pure solvent was pumped 
through the system until the instrument had achieved the desired reaction 
parameters and stable processing was achieved. At that point the sample inlet 
line was switched to the vial containing the substrate. A total reaction volume 
of 15 mL was collected and the cartridge subsequently washed with pure 
solvent for 5 min to remove any substrate/product still adsorbed on the 
catalyst. Evaporation of the solvent afforded 53b as a yellow oil (97% crude 
yield), which was purified by flash chromatography to provide 0.84 g of a 
pale-yellow oil (94%). 
1
H NMR (300 MHz, CDCl3): δ 7.117.08 (m, 2H); 
6.846.81 (m, 2H); 3.78 (s, 3H); 2.872.81 (m, 2H); 2.752.70 (m 2H); 2.13 
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Synthesis of 4-(4-hydroxyphenyl)-3-buten-2-one (52c) 
 
Batch Microwave Synthesis: MizorokiHeck Reaction. To 1 mL of DMF/ H2O 
(3:1) as solvent in a 10-mL Pyrex microwave vial were added 4-iodoanisole 
(0.09 g, 0.43 mmol), methyl vinyl ketone (52.0 μL, 0.64 mmol) and Cs2CO3 
(0.15 g, 0.47 mmol), followed by 2 mL of 0.0004 M stock solution of 
Pd(OAc)2 in DMF/H2O (3:1) (0.19 mg, 0.2 mol %). The reaction mixture was 
stirred for 30 s, capped with a Teflon septum, and subjected to microwave 
heating for 20 min (hold time) at 160 °C. After cooling to ambient 
temperature, the crude reaction mixture was concentrated under reduced 
pressure and the residue subjected to automated flash chromatography with 
petroleum ether/ethyl acetate (0 to 45% gradient) as eluent to provide 0.05 g 
(78%) of 52c.White solid, mp 111113 °C. 
1
H NMR (300 MHz, CDCl3): δ 
7.527.43 (m, 3H); 6.916.86 (m, 2H); 6.61 (d, J = 16.2 Hz, 1H); 6.09 (br s, 




Batch Microwave Synthesis: Wittig Reaction. To a solution of 
(acetylmethylene)triphenylphosphorane (0.19 g, 0.61 mmol) in 3 mL of DMF, 
was added 4-hydroxybenzaldehyde (0.04 g, 0.36 mmol), and the mixture was 
stirred for 30 s in a 10-mL Pyrex vial. The solution was capped with a Teflon 
septum and heated by microwave irradiation at 210 °C for 10min. After 
cooling the vessel to ambient conditions, the crude reaction mixture was 
concentrated under reduced pressure and transferred to a silica-samplet, dried 
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chromatography with petroleum ether/ethyl acetate (0 to 45% gradient) as 
eluent to provide 0.04 mg (70%) of 52c. 
 
Batch Microwave Synthesis: Aldol Condensation. To a solution of 4-
hydroxybenzaldehyde (0.30 g, 2.50 mmol) in 2 mL of acetone was added 2 
mL of a 10% aqueous NaOH solution, and the mixture was stirred for 30 s in a 
10-mL Pyrex vial. The solution was capped with a Teflon septum and heated 
by microwave irradiation at 70 °C for 450 s. After cooling the vessel to 
ambient conditions, the crude reaction mixture was concentrated under 
reduced pressure and transferred to a silica-samplet, dried for 1 h at 50 °C in a 
drying oven, and subjected to automated flash chromatography with petroleum 
ether/ethyl acetate (0 to 45% gradient) as eluent to provide 0.28 g (69%) of 
52c. 
 
Continuous Flow Synthesis: Wittig Reaction. To a solution of 
(acetylmethylene)triphenylphosphorane (0.65 g, 2.04 mmol) in 10 mL of DMF 
was added 4-hydroxybenzaldehyde (0.15 g, 1.20 mmol), and the mixture was 
stirred for 30 s in a 15-mL Pyrex vial. At the same time the FlowSyn reactor 
was equipped with a stainless steel reaction coil (10 mL volume, 10 min 
residence time at 1 mL/min flow rate). The reaction parameters temperature 
(210 °C) and 1 mL/min flow rate were selected on the flow reactor, and 
processing was started, whereby initially only solvent DMF was pumped 
through the system until the instrument had achieved the desired reaction 
parameters and stable processing was achieved. At that point the inlet tube was 
switched from the solvent flask to the 15 mL glass vial containing the reaction 
mixture. After processing through the flow reactor, the inlet flow was dipped 
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thus washing from the system any remaining reaction mixture. The reaction 
was concentrated under vacuum and 0.19 g (98%) of product. 
 
Continuous Flow Synthesis: Aldol Reaction. To a solution of 4-
hydroxybenzaldehyde (0.76, 6.25 mmol) in 5 mL of acetone was added 5 mL 
of a 10% aqueous NaOH solution, and the solution was stirred for 30 s. At the 
same time the FlowSyn reactor was equipped with a stainless steel reaction 
coil (10 mL volume, 450 s residence time at 1.34 mL/min flow rate). The 
reaction parameters temperature (70 °C) and 1.34 mL/min flow rate were 
selected on the flow reactor, and processing was started, whereby initially only 
solvent acetone was pumped through the system until the instrument had 
achieved the desired reaction parameters and stable processing was achieved. 
At that point the inlet tube was switched from the solvent flask to the 15 mL 
glass vial containing the freshly prepared reaction mixture (a slow aldol 
condensation occurs also at room temperature). After processing through the 
flow reactor, the inlet flow was dipped back into the flask containing solvent 
and processed for an additional 1 min, thus washing from the system any 
remaining reaction mixture. The reaction was concentrated under vacuum and 
0.79 mg (78%) of product. 
Synthesis of 4-(4-hydroxyphenyl)-butan-2-one (53c)  
 
A 10 mL stock solution of 52c with a 0.7 M concentration in DMF was 
prepared in a glass vial. The reaction parameters (Full-H2 mode, 35 °C and 1 
mL/min flow-rate) were selected on the H-Cube hydrogenator. The instrument 
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whereby initially only pure solvent was pumped through the system until the 
instrument had achieved the desired reaction parameters and stable processing 
was achieved. At that point the sample inlet line was switched to the vial 
containing the substrate. A total reaction volume of 15 mL was collected and 
the cartridge subsequently washed with pure solvent for 5 min to remove any 
substrate/product still adsorbed on the catalyst. Evaporation of the solvent 
affords 53c as a yellow oil (97% crude yield), which was purified by flash 
chromatography to provide 1.04 g of a pale yellow oil (91%).
1
H NMR (300 
MHz, CDCl3): δ 7.077.02 (m, 2H); 6.766.73 (m, 2H); 4.86 (br s, 1H); 





7.4. DNMT1 expression, purification, and assay 
Cloning and purification of recombinant DNMT1. Briefly, proteins were 
expressed in Sf9 insect cells (derived from Spodoptera frugiperda) and 
purified by affinity chromatography and gel filtration. The protein 
concentration of purified DNMT was determined by Bradford assay and 
verified by using Coomassie blue stained SDS/polyacrylamide gels and 
suitable molecular mass markers of known concentration. Protein identity was 
confirmed by immunoblotting using a DNMT1-specific antibody (Santa Cruz) 
according to the manufacturer‟s protocol. 
Biochemical DNMT activity assay and dose-response assays. DNA 
methylation assays were carried out in total reaction volume of 25 μL 
containing 0.4 μM hemimethylated or unmethylated oligonucleotide substrate 
purchased from MWG (upper strand: 5ꞌ-
GATCGCXGATGCGXGAATXGCGATXGATGCGAT-3ꞌ, X = 5mC for 
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ATCGCATCGATCGCGATTCGCGCATCGGCGATC-3ꞌ), purified DNMT 
(500 nM) in reaction buffer (100 mM KCl, 10 mM TrisCl pH 7.5, 1 mM 
EDTA), and BSA (1 mg/mL). All reactions were carried out at 37 °C in the 
presence of 0.7 μM [methyl-
3
H] AdoMet (2.6 TBq/mmol, PerkinElmer). After 
3 h, the reaction was stopped by adding 10 μL of 20% SDS and spotting of the 
whole volume onto DE81 cellulose paper. Filters were baked at 80 °C for 2 h 
and washed three times with cold 0.2M NH4HCO3, three times with distilled 
water, and once with 100% ethanol. After drying, filters were transferred into 
Mini-Poly Q vial (PerkinElmer) and 5 mL of Ultima Gold LSC Cocktail was 
added per vial. Analysis was done in a scintillation counter, each measurement 
was repeated once. 
Competition assay. For the determination of the mode of action of 5b in the 
catalytic domain of DNMT1, we used the model of Lai and Wu as 
recommended by the NIH Chemical Genomics Center 
(http://www.ncgc.nih.gov/guidance) and adapted it to our biochemical DNMT 
activity assay. The conditions of the biochemical DNMT activity assay (see 
above) were slightly modified for the competition experiments: the inhibitor 
concentration was held constant at 150 μM, the reaction time at 37 °C was 
decreased to 1 h. The concentrations of either SAM substrate or oligo substrate 
were increased to test for competition with 5b, which should result in a 
decreasing inhibition. 
Cell culture. HCT116 cells were obtained directly from the American Type 
Culture Collection (ATCC, www.atcc.org) and passaged for fewer than 6 
months after resuscitation. HCT116 were cultured in DMEM/Ham‟s F12 
(BIOCHROM) supplemented with 10% FCS (Invitrogen). Cell proliferation 
and viability was assessed by counting trypan blue stained cells by TC10 
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